HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Web of Science (134) Citing Articles via Google Scholar Google Scholar Articles by Orshal, J. M. Articles by Khalil, R. A. Search for Related Content PubMed PubMed Citation Articles by Orshal, J. M. Articles by Khalil, R. A.

INVITED REVIEW

Gender, sex hormones, and vascular tone

Research and Development, Department of Veterans Affairs Medical Center, West Roxbury; and Department of Medicine, Harvard Medical School, Boston, Massachusetts 02132

	ABSTRACT

TOP ABSTRACT GENDER DIFFERENCES IN VASCULAR... SEX HORMONE RECEPTORS IN... GENOMIC EFFECTS OF SEX... NONGENOMIC EFFECTS OF SEX... SEX HORMONES AND THE... SEX HORMONES AND NO SEX HORMONES AND PGI2 SEX HORMONES AND EDHF SEX HORMONES AND ENDOTHELIUM... SEX HORMONES AND VSM... SIGNALING MECHANISMS OF VSM... SEX HORMONES AND VSM... SEX HORMONES AND PKC GRANTS REFERENCES

 
The greater incidence of hypertension and coronary artery disease in men and postmenopausal women compared with premenopausal women has been related, in part, to gender differences in vascular tone and possible vascular protective effects of the female sex hormones estrogen and progesterone. However, vascular effects of the male sex hormone testosterone have also been suggested. Estrogen, progesterone, and testosterone receptors have been identified in blood vessels of human and other mammals and have been localized in the plasmalemma, cytosol, and nuclear compartments of various vascular cells, including the endothelium and the smooth muscle. The interaction of sex hormones with cytosolic/nuclear receptors triggers long-term genomic effects that could stimulate endothelial cell growth while inhibiting smooth muscle proliferation. Activation of plasmalemmal sex hormone receptors may trigger acute nongenomic responses that could stimulate endothelium-dependent mechanisms of vascular relaxation such as the nitric oxide-cGMP, prostacyclin-cAMP, and hyperpolarization pathways. Additional endothelium-independent effects of sex hormones may involve inhibition of the signaling mechanisms of vascular smooth muscle contraction such as intracellular Ca²⁺ concentration and protein kinase C. The sex hormone-induced stimulation of the endothelium-dependent mechanisms of vascular relaxation and inhibition of the mechanisms of vascular smooth muscle contraction may contribute to the gender differences in vascular tone and may represent potential beneficial vascular effects of hormone replacement therapy during natural and surgically induced deficiencies of gonadal hormones.

estrogen; progesterone; testosterone; endothelium; nitric oxide; vascular smooth muscle; calcium

The purpose of this review is to provide an insight into the gender differences in vascular tone and the effects of sex hormones on vascular cells, namely the endothelium and smooth muscle. We will first provide an overview on vascular tone and its modification with gender. The vascular sex hormone receptors, agonists, and antagonists will then be described. We will follow with a description of the genomic effects of sex hormones on endothelial as well as VSM cell growth and proliferation. The nongenomic effects of sex hormones on the endothelium-dependent mechanisms of vascular relaxation will then be discussed. We will follow with a detailed description of the effects of sex hormones on the signaling mechanisms of VSM contraction. The review will end with a perspective on potential areas for future investigations to better understand the mechanisms underlying the gender differences and the effects of sex hormones on vascular tone and the possible clinical uses of HRT to reduce the incidence of cardiovascular disease.

	GENDER DIFFERENCES IN VASCULAR TONE

TOP ABSTRACT GENDER DIFFERENCES IN VASCULAR... SEX HORMONE RECEPTORS IN... GENOMIC EFFECTS OF SEX... NONGENOMIC EFFECTS OF SEX... SEX HORMONES AND THE... SEX HORMONES AND NO SEX HORMONES AND PGI2 SEX HORMONES AND EDHF SEX HORMONES AND ENDOTHELIUM... SEX HORMONES AND VSM... SIGNALING MECHANISMS OF VSM... SEX HORMONES AND VSM... SEX HORMONES AND PKC GRANTS REFERENCES

 
Vascular tone is defined as the degree of constriction of a blood vessel relative to its maximal diameter in the dilated state. Under basal conditions, most resistance and capacitance vessels exhibit some degree of smooth muscle contraction that determines the diameter or tone of the vessel. Vascular tone is influenced by both the endothelium and VSM. The vascular tone is also determined by a multitude of vasoconstrictor factors such as norepinephrine, ANG II, vasopressin, and 5-hydroxytryptamine as well as vasodilator factors such as bradykinin and prostacyclin (PGI₂). These factors can be divided into extrinsic factors that originate from outside the blood vessel and intrinsic factors that originate from the vessel itself. Extrinsic factors primarily serve the function of regulating arterial pressure by altering systemic vascular resistance, whereas intrinsic mechanisms are concerned with regulation of local blood flow within an organ (30).

Gender differences in vascular tone have been described in a multitude of vascular beds in both human and experimental animals (123). For example, -adrenergic agonists such as norepinephrine cause less forearm vasoconstriction in women than in men (77). Also, oxidized low-density lipoprotein enhances 5-hydroxytryptamine-induced contraction to a greater extent in coronary arteries from male than female pigs (23). In addition, the contraction to norepinephrine or phenylephrine (Phe) is greater in the aorta of intact male than intact female rats (25, 123). Interestingly, vasopressin-induced contraction in rat aorta exhibits sexual dimorphism, but the contraction in females is almost twice that in males (123). The difference could be related to possible tachyphylactic effects of vasopressin in isolated vessels, which are different from its effects in vivo. This is supported by reports that the pressor response to vasopressin infusion in vivo is greater in male than female rats (123).

We recently found that the vascular contraction is not different between castrated and intact male rats, but significantly enhanced in ovariectomized (OVX) females compared with intact females, suggesting that the gender differences in vascular tone are less likely related to androgens and more likely related to estrogens (25, 69). The data also suggest that the gender differences in vascular tone are due to direct vascular effects of sex hormones, possibly through interaction with specific hormone receptors in the vasculature.

	SEX HORMONE RECEPTORS IN BLOOD VESSELS

TOP ABSTRACT GENDER DIFFERENCES IN VASCULAR... SEX HORMONE RECEPTORS IN... GENOMIC EFFECTS OF SEX... NONGENOMIC EFFECTS OF SEX... SEX HORMONES AND THE... SEX HORMONES AND NO SEX HORMONES AND PGI2 SEX HORMONES AND EDHF SEX HORMONES AND ENDOTHELIUM... SEX HORMONES AND VSM... SIGNALING MECHANISMS OF VSM... SEX HORMONES AND VSM... SEX HORMONES AND PKC GRANTS REFERENCES

 
Receptors for estrogen, progesterone, and testosterone are expressed in varying numbers in both the endothelium and VSM of multiple vascular systems (75, 129). For instance, a significant association between the number of estrogen receptors (ER) and normal endothelial cell function has been reported, and suggested that decreased number of endothelial ER may represent a risk factor for cardiovascular diseases (109). Also, the sex hormone receptors appear to have different subtypes, tissue distribution, and subcellular location and can be modulated by various agonists and antagonists (Table 1).

Two ER subtypes have been identified, ER- and ER- (84). Several variants of ER-, such as ER-A, ER-C, ER-E, and ER-F (79), as well as ER-, such as ER-1, ER-2, ER-4, and ER-5, have been described (14, 115). Some studies suggest that ER- promotes the protective effects of estrogen in response to vascular injury (98). However, ER- is more widely distributed in the body than ER-. Also, ER- is the receptor form that is predominantly expressed in human VSM, particularly in women (84). Induction of ER- mRNA expression has also been demonstrated after balloon vascular injury to the aorta of the male rat. Furthermore, experiments on transfected HeLa cells have shown that in response to 17-estradiol (E₂), ER- is a stronger transactivator than ER- at low receptor concentrations. However, at higher receptor concentrations, ER- activity self-squelches, and ER- becomes the stronger transactivator. These data support a role for ER- in the direct vascular effects of estrogen and in the regulation of vascular function (57).

ERs have been localized in the nucleus, and continuous shuttling of the receptor between the cytoplasm and the nucleus has been suggested (49). Sex steroids, such as estrogen, diffuse through the plasma membrane and form complexes with specific cytosolic and/or nuclear receptors, which then bind to chromatin and stimulate the transcription of a set of genes with a specific sex steroid-responsive regulatory element (60, 80) (Fig. 1). ER-mediated transcription requires coactivators to exert transcriptional activity. The steroid receptor coactivator-3 (SRC-3) is highly expressed in VSM. SRC-3 interacts with estrogen-bound ERs and coactivates the transcription of target genes in cultured VSM cells, suggesting that SRC-3 facilitates ER-dependent vasoprotective effects during vascular injury (144). However, estrogen can also bind to the plasma membrane of various vascular cells and induce rapid cellular events, suggesting additional nongenomic action triggered by a signal-generating receptor on the cell surface (26, 38). Recent studies also suggest possible interactions of ER with signal-modulating proteins or coactivators in the plasma membrane (103).

View larger version (53K): [in this window] [in a new window]   Fig. 1. Estrogen-stimulated endothelium-dependent mechanisms of vascular smooth muscle (VSM) relaxation. In the genomic pathway, estrogen binds to endothelial cytosolic/nuclear estrogen receptors (ER), leading to activation of mitogen-activated protein kinase (MAPK), increased gene transcription, endothelial cell proliferation, and increased endothelial nitric oxide synthase (eNOS) production. In the nongenomic pathway, estrogen binds to endothelial surface membrane ERs, which are coupled to increased Ca2+ release from the endoplasmic reticulum and stimulation of MAPK/Akt pathway, leading to activation of eNOS and increased nitric oxide (NO) production. NO diffuses into the VSM cells, binds to guanylate cyclase (GC), and increases cGMP. cGMP causes VSM relaxation by decreasing [Ca2+]i and the myofilament sensitivity to Ca2+. ER may also inhibit the production of NADPH, thereby preventing the inactivation of NO and the formation of peroxynitrites (ONOO-). Endothelial ER may also activate cyclooxygenases (COX) and increase PGI2 production. PGI2 activates prostacyclin receptors in VSM, activates adenylate cyclase (AC), and increases the formation of cAMP. cAMP causes VSM relaxation by mechanisms similar to those activated by cGMP. ER may also increase the production of endothelium-derived hyperpolarizing factor (EDHF), which activates K+ channels and causes hyperpolarization and inhibition of Ca2+ influx via Ca2+ channels leading to VSM relaxation. Interrupted arrows indicate inhibition. L-arg, L-arginine; L-cit, L-citrulline; AA, arachidonic acid.

Another hormone receptor that has been located in the endothelium and VSM is the progesterone receptor (129, 135). Progesterone receptor-A and -B have been identified (97). Progesterone receptors, particularly the B isoform, appear to have a direct role in the regulation of gene transcription and VSM cell proliferation (99).

Testosterone or androgen receptors have also been identified in endothelial cells and VSM. The expression of androgen receptors in VSM appears to vary depending on the gender and the status of the gonads. The androgen receptor protein, as detected by Western blot in rat aortic VSM, is less in the cells of females than those of males (55). In the smooth muscle of primates, androgen receptor mRNA levels are upregulated by combined estradiol plus testosterone treatment, whereas estradiol treatment alone had little or no effect, suggesting that a collaborative action of estradiol and testosterone enhances androgen receptor expression (142).

	GENOMIC EFFECTS OF SEX HORMONES

TOP ABSTRACT GENDER DIFFERENCES IN VASCULAR... SEX HORMONE RECEPTORS IN... GENOMIC EFFECTS OF SEX... NONGENOMIC EFFECTS OF SEX... SEX HORMONES AND THE... SEX HORMONES AND NO SEX HORMONES AND PGI2 SEX HORMONES AND EDHF SEX HORMONES AND ENDOTHELIUM... SEX HORMONES AND VSM... SIGNALING MECHANISMS OF VSM... SEX HORMONES AND VSM... SEX HORMONES AND PKC GRANTS REFERENCES

 
The interaction of sex hormones with nuclear/cytosolic receptors triggers a host of genomic effects leading to endothelial cell growth. The effects of sex hormones on endothelial cell growth appear to be mediated by activation of mitogen-activated protein kinase (MAPK; Fig. 1). This is supported by reports that E₂ induces the phosphorylation of p38 and p42/44 MAPK as well as the migration and proliferation of porcine aortic endothelial cells (42).

Although estradiol activates signaling pathways that stimulate endothelial cell proliferation, the steroid appears to inhibit cell growth and to induce antiproliferative effects in VSM (33). For example, the rate of growth in VSM of female aorta is slower than that in male aorta (3). The inhibitory effects of estrogen on VSM growth may be enhanced by its interaction with steroid receptor coactivators such as SRC-3 (144). Estrogen has also been shown to inhibit MAPK activity in VSM, and this effect is blocked by the estrogen antagonist ICI-182780, suggesting that inhibition of the MAPK pathway via ERs contributes to the inhibitory effects of estrogen on VSM growth (33). Estrogen may also antagonize the growth-promoting effect of ANG II on VSM via the induction and activation of protein phosphatases through genomic as well as nongenomic mechanisms (126). Interestingly, nitric oxide (NO) has been shown to inhibit VSM growth and proliferation. Whether an estrogen-induced increase in NO production plays a role as a possible mediator of estrogen-induced inhibition of VSM growth remains to be clarified. Furthermore, estradiol may stimulate cAMP production and the cAMP-derived adenosine may regulate VSM growth via adenosine receptors, suggesting that the cAMP/adenosine pathway may contribute to the antiproliferative effects of estradiol (34).

Progesterone also inhibits VSM proliferation and migration and may facilitate the inhibitory effects of estrogen. Progesterone appears to mediate its inhibitory effects on VSM growth by reducing MAPK activity (93).

Some studies have suggested that androgens accelerate vascular growth by stimulating the proliferation of VSM, whereas other studies show androgen-induced inhibition of growth and proliferation (121, 142). The discrepancy in these reports may be related to the concentration of androgens used. Androgens may control the proliferation of their target cells by first increasing cell proliferation and later by inhibiting the proliferation of the same cells. For example, dihydrotestosterone modulates human umbilical VSM cell proliferation in a dose-dependent manner, with low concentrations (3 nM) stimulating [³H]thymidine incorporation, and high concentrations (300 nM) inhibiting [³H]thymidine incorporation (121, 142).

We should note that the genomic effects of sex hormones may alter the expression of a multitude of regulatory and signaling proteins in endothelial cells and VSM. To avoid repetition, these genomic effects will be described with the nongenomic effects of sex hormones on the endothelium and VSM as described below.

	NONGENOMIC EFFECTS OF SEX HORMONES

TOP ABSTRACT GENDER DIFFERENCES IN VASCULAR... SEX HORMONE RECEPTORS IN... GENOMIC EFFECTS OF SEX... NONGENOMIC EFFECTS OF SEX... SEX HORMONES AND THE... SEX HORMONES AND NO SEX HORMONES AND PGI2 SEX HORMONES AND EDHF SEX HORMONES AND ENDOTHELIUM... SEX HORMONES AND VSM... SIGNALING MECHANISMS OF VSM... SEX HORMONES AND VSM... SEX HORMONES AND PKC GRANTS REFERENCES

 
The interaction of sex hormones with plasmalemmal receptors in the endothelium and VSM may initiate additional nongenomic vascular effects. For example, estrogen may induce acute inhibition of vascular contraction (24, 129). Also, progestins may have direct vascular effects or modify the effects of estrogen on vascular contraction (24). Interestingly, direct vascular effects of testosterone have also been described (142, 145). For example, testosterone induces pulmonary and coronary artery dilation (24, 145). The acute nongenomic vasodilator effects of sex hormones appear to have both endothelium-dependent as well as endothelium-independent mechanisms involving direct effects on VSM.

	SEX HORMONES AND THE ENDOTHELIUM

TOP ABSTRACT GENDER DIFFERENCES IN VASCULAR... SEX HORMONE RECEPTORS IN... GENOMIC EFFECTS OF SEX... NONGENOMIC EFFECTS OF SEX... SEX HORMONES AND THE... SEX HORMONES AND NO SEX HORMONES AND PGI2 SEX HORMONES AND EDHF SEX HORMONES AND ENDOTHELIUM... SEX HORMONES AND VSM... SIGNALING MECHANISMS OF VSM... SEX HORMONES AND VSM... SEX HORMONES AND PKC GRANTS REFERENCES

 
The vascular endothelium plays an important role in mediating the gender-related and the estrogen-induced vasodilation (72). Physiological levels of E₂ potentiate endothelium-dependent flow-mediated vasodilation in postmenopausal women (45). Also, endothelium-dependent relaxation of isolated aorta is greater in female than in male spontaneously hypertensive rats (SHR; 67, 72). Similar to estrogen, progesterone may promote endothelium-dependent vasodilation in porcine coronary artery (92). Also, some studies have shown that testosterone induces endothelium-dependent vascular relaxation (20, 22). The vascular endothelium is known to release relaxing factors such as NO, prostacyclin (PGI₂), and endothelium-derived hyperpolarizing factor (EDHF), as well as contracting factors such as endothelin (ET-1) and thromboxane A₂, and the sex hormones appear to induce vascular relaxation by modifying the synthesis/release/bioactivity of one or more of these factors.

	SEX HORMONES AND NO

TOP ABSTRACT GENDER DIFFERENCES IN VASCULAR... SEX HORMONE RECEPTORS IN... GENOMIC EFFECTS OF SEX... NONGENOMIC EFFECTS OF SEX... SEX HORMONES AND THE... SEX HORMONES AND NO SEX HORMONES AND PGI2 SEX HORMONES AND EDHF SEX HORMONES AND ENDOTHELIUM... SEX HORMONES AND VSM... SIGNALING MECHANISMS OF VSM... SEX HORMONES AND VSM... SEX HORMONES AND PKC GRANTS REFERENCES

 
NO is a powerful vasodilator and relaxant of VSM. NO is produced from the transformation of L-arginine to L-citrulline by the enzyme NO synthase (NOS; Figs. 1 and 2). Three NOS isoforms have been described: neuronal nNOS (NOS I), inducible iNOS (NOS II), and endothelial eNOS (NOS III; 141). iNOS is Ca²⁺ independent and may be involved in long-term regulation of vascular tone, whereas eNOS is Ca²⁺ dependent and plays a role in the short-term regulation of vascular tone.

View larger version (47K): [in this window] [in a new window]   Fig. 2. Estrogen-stimulated NO production in endothelial cell caveola. Estrogen binds to endothelial surface membrane ER and increases the formation of inositol 1,4,5-trisphosphate (IP3), which stimulates Ca2+ release from the endoplasmic reticulum. Ca2+ forms a complex with calmodulin (CAM), which in turn binds to and causes initial activation of eNOS, its dissociation from caveolin-1, and its translocation to intracellular sites. Estrogen may also activate phosphatidylinositol 3-kinase (PI3-K), leading to transformation of phosphatidylinositol-4,5-bisphosphate (PIP2) into phosphatidylinositol 3,4,5-trisphosphate (PIP3), which could activate Akt. ER-mediated activation of Akt or MAPK pathway causes phosphorylation of cytosolic eNOS and its second translocation back to the cell membrane where it undergoes myristoylation and palmitoylation, a process required for its full activation. Activated eNOS promotes the transformation of L-arginine to L-citrulline and the production of NO, which diffuses through the endothelial cell caveola and causes VSM relaxation.

Under basal conditions, eNOS is firmly attached to the inhibitor protein caveolin, a scaffolding transmembrane protein in the plasma membrane caveolae (Fig. 2). Agonist activation of endothelial cells causes an increase in intracellular Ca²⁺ concentration ([Ca²⁺]_i) and an initial activation of eNOS. The initial Ca²⁺-dependent activation of eNOS involves its dissociation from caveolin and its translocation to intracellular sites close to the nucleus. During maintained endothelial cell stimulation with an agonist, activation of MAPK and/or the protein kinase B/Akt pathway and subsequent phosphorylation of eNOS causes a second translocation of cytosolic eNOS back to the cell membrane where it undergoes myristoylation and palmitoylation, a process required for its full activation (Fig. 2). These rapid receptor-mediated effects on the NO pathway are seen not only for "classic" eNOS agonists, such as ACh and bradykinin, but also for estradiol (86; Figs. 1 and 2).

Total NO production is greater in premenopausal women than in men (39). The cellular origin of the increased NO in women is not entirely clear, but differences in vascular endothelial NO production may underlie the gender differences in vascular tone (39). NO release from the endothelium is increased in arteries of females compared with males (71, 78, 139). This is supported by reports that the inhibitory effect of the NOS inhibitor N-L-arginine methyl ester (L-NAME) on ACh-induced relaxation is more pronounced in the mesenteric artery of female than male rats (67). Estrogen appears to be responsible for the gender differences in endothelial NO release (28, 41, 78, 85). E₂ replacement in OVX female guinea pigs enhances the sensitivity to vasodilators in the coronary microcirculation through increased endothelial NO production (130). Also, prolonged treatment of human coronary endothelial cells with E₂ increases the basal, adenosine triphosphate-, and A23187 [GenBank] -induced NO release (143).

Estrogen may influence NO production by increasing NOS expression (41, 78). Activation of genomic ERs may cause upregulation of eNOS (71; Fig. 1). It has been shown that ER- gene transfer into bovine aortic endothelial cells induces eNOS gene expression (128). Also, estrogen increases the level of eNOS mRNA in ovine fetal pulmonary artery endothelial cells (83). Estrogen may also prevent destabilization of eNOS mRNA induced by tumor necrosis factor- through an ER-mediated mechanism (125).

In addition to the genomic effects of estrogen on eNOS expression, estrogen may regulate NOS activity and thereby NO production and vascular tone by interacting with specific ERs in the endothelial cell plasma membrane and activation of rapid nongenomic signaling pathways (41, 78). Membrane-impermeant forms of estrogen bind to specific ERs at the cell surface and stimulate NO release from human endothelial cells (112). Also, in bovine aortic endothelial cells, E₂ causes transient translocation of eNOS from the plasma membrane to intracellular sites close to the nucleus, although during prolonged exposure to E₂, most of the eNOS returns to the plasma membrane for its full activation (86).

The acute effect of E₂ on eNOS activity and NO release has been suggested to occur via activation of ER- in COS-7 cells (19) and mouse aorta (27). However, studies have shown that overexpression of ER- in COS-7 cells enhances rapid eNOS activation by E₂ and the ER- protein association to the plasma membrane caveolae and that these events occur independent of ER-. These findings indicate that endogenous ER- also plays a prominent role in the nongenomic effects of E₂ on eNOS activity (17).

The acute effects of E₂ on eNOS activity and NO release appear to be dependent on [Ca²⁺]_i. Gender differences in the regulation of endothelial [Ca²⁺]_i have been related to direct or indirect effects of estrogen on the Ca²⁺ handling mechanisms in the vascular endothelium (78, 102, 139). Estrogen activation of cell surface ERs has been suggested to be coupled to increases in [Ca²⁺]_i and acute stimulation of NO release from human endothelial cells (124). Studies have also suggested possible gender differences in the eNOS sensitivity to [Ca²⁺]_i. Experiments on pressurized coronary arteries of rats have shown that increases in [Ca²⁺]_i cause activation of eNOS with a similar slope and half-activation constant for both female and male arteries. However, at [Ca²⁺]_i > 100 nM, eNOS activity is higher in females compared with males (78). Interestingly, E₂ may promote the association of heat shock protein 90 with eNOS and thereby reduce the Ca²⁺ requirement for eNOS activation (112). However, E₂ may stimulate eNOS activity and increase NO release from human endothelial cells, independent of cytosolic Ca²⁺ mobilization (16), perhaps through eNOS phosphorylation via a mechanism involving MAPK or Akt (56, 112). In studies of ovine endothelial cells, E₂ caused acute activation of eNOS as well as rapid activation of MAPK, and inhibition of MAPK kinase prevented the activation of eNOS by E₂. These data suggest that the acute vascular effects of estrogen are mediated by ER functioning in a nongenomic manner to activate eNOS via MAPK-dependent mechanisms (19). Also, E₂ rapidly induces phosphorylation and activation of eNOS through the phosphatidylinositol-3 (PI₃)-kinase-Akt pathway and thereby reduces its [Ca²⁺]_i requirement for activation (52; Fig. 2).

The effects of estrogen on the NO pathway may also be related to its antioxidant effects. It has been shown that the increase in arterial pressure in OVX female rats is associated with lower plasma antioxidant levels, reduced thiol groups, and increased plasma lipoperoxides and vascular free radicals, and that estrogen replacement prevents the increase in free radicals and the decrease in plasma levels of nitrites/nitrates (54). Also, E₂ inhibits NADPH oxidase expression and the generation of reactive oxygen species and peroxynitrite (ONOO^-) in human umbilical vein endothelial cells (136; Fig. 1). ANG II stimulation of endothelial cells has been shown to increase the expression of NADPH oxidase, which may contribute to oxidative stress, as evidenced by ONOO^- formation. E₂ appears to inhibit ANG II-induced increases in oxidative-stress effects, possibly through reduced ANG II type 1 receptor expression (46). Also, measurements of superoxide anion (O₂^-) in the isolated aorta have shown greater amounts in male than in female rats (12). Furthermore, estrogen decreases the generation of O₂^- from cultured bovine aortic endothelial cells and thereby enhances NO bioactivity and decreases ONOO^- release (5). These data suggest that the decrease in vascular tone and arterial pressure with estrogen administration may be related to preventing oxidative stress and improving endothelial function.

Although gender and estrogen treatment may affect NO production/bioactivity, their influence on factors downstream in the NO signaling pathway is unclear. NO produced from the endothelium is known to activate guanylate cyclase in the smooth muscle leading to increased cGMP and stimulation of cGMP-dependent protein kinase (PKG; 140). PKG may decrease [Ca²⁺]_i by stimulating Ca²⁺ extrusion pumps in the plasma membrane and Ca²⁺ uptake pumps in the sarcoplasmic reticulum membrane and/or decrease the sensitivity of the contractile myofilaments to [Ca²⁺]_i and thereby promote VSM relaxation (Fig. 1). It has been shown that the relaxation of mesenteric arterial rings by the exogenous NO donor sodium nitroprusside is greater in female than male SHR (67), suggesting gender differences in smooth muscle reactivity to NO and possible hormonal regulation of PKG. However, in aortic rings from male and female SHR, sodium nitroprusside-induced relaxation is similar, making the possibility of gender differences in smooth muscle reactivity to NO and the hormonal regulation of PKG rather less likely (72).

Carbon monoxide is formed by heme oxygenase-2 in the vascular endothelium and has been found to activate soluble guanylate cyclase and dilate blood vessels independently from NO. Because of the parallels between NO and carbon monoxide, it has been suggested that estrogen might affect carbon monoxide production in vascular endothelium. Studies in human umbilical vein and uterine artery endothelial cells have shown that treatment with E₂ causes significant increases in intracellular carbon monoxide production, heme oxygenase-2 protein levels, and cellular cGMP, suggesting a potential role for carbon monoxide as a biological messenger molecule in estrogen-mediated regulation of vascular tone (133).

The effects of progesterone on the vascular endothelium are less clear. Experimental studies on canine coronary arteries have suggested that progesterone may counteract the stimulatory effects of estrogen on endothelium-dependent NO production and vascular relaxation (88). However, studies in postmenopausal women have shown that progesterone does not appreciably attenuate estradiol-induced endothelium-dependent vasodilation of the brachial artery (44). Other studies have shown that progesterone may stimulate NO production in rat aortic strips (116) and induce endothelium-dependent NO-mediated relaxation in rat resistance mesenteric arteries (18). Also, intravenous infusion of progesterone in pigs has been shown to induce endothelium-dependent coronary vasodilation via a mechanism involving the release of NO (92). Furthermore, chronic administration of progesterone has been shown to increase the expression of eNOS in the endothelium of ovine uterine artery (111).

In regard to testosterone, acute intracoronary administration of the hormone in canine coronary epicardial and resistance vessels has been shown to induce vasodilation that is mediated in part by NO (20). Testosterone may also modulate the effects of other agonists on endothelial NO production. Bradykinin, a known activator of endothelium-dependent NO pathway, has been shown to increase intracellular inositol 1,4,5-trisphosphate (IP₃) and stimulate rapid release of Ca²⁺ from the endoplasmic reticulum in cultured endothelial cells of male rats. Treatment of the cells with testosterone blocks bradykinin-induced increases in [Ca²⁺]_i and thereby NO production in endothelial cells, perhaps through an effect of testosterone on membrane-bound bradykinin receptors or on bradykinin-induced Ca²⁺ release mechanism (110). Recent studies have shown that treatment of human endothelial cells with androgens such as dehydroepiandrosterone (DHEA) triggers NO synthesis by enhancing the expression and stabilization of eNOS. DHEA appears to activate eNOS through an MAPK-dependent mechanism, but not the PIP₃ kinase/Akt pathway (120). Also, administration of DHEA in ovariectomized female Wistar rats has been shown to restore aortic eNOS levels and eNOS activity (120). Interestingly, androgen antagonists such as flutamide may also affect the NO pathway. It has been shown that flutamide produces direct vasodilation by inducing NO release from the endothelium and subsequent activation of guanylyl cyclase in rat aortic smooth muscle; however, these vascular effects of flutamide do not appear to be mediated via androgen receptors (61). Additionally, administration of flutamide reduces blood pressure in hypertensive transgenic TGR(mREN2)27 rats, which have an overactive renin-angiotensin system. Furthermore, flutamide reduces the blood pressure in TGR(mREN2)27 rats with an additional testicular feminizing mutation (tfm), suggesting that the vascular effects of flutamide may be caused by androgen receptor-independent mechanisms (61).

	SEX HORMONES AND PGI2

TOP ABSTRACT GENDER DIFFERENCES IN VASCULAR... SEX HORMONE RECEPTORS IN... GENOMIC EFFECTS OF SEX... NONGENOMIC EFFECTS OF SEX... SEX HORMONES AND THE... SEX HORMONES AND NO SEX HORMONES AND PGI2 SEX HORMONES AND EDHF SEX HORMONES AND ENDOTHELIUM... SEX HORMONES AND VSM... SIGNALING MECHANISMS OF VSM... SEX HORMONES AND VSM... SEX HORMONES AND PKC GRANTS REFERENCES

 
PGI₂ is an endothelium-derived relaxing factor that is produced from the metabolism of arachidonic acid by the enzyme cyclooxygenase (COX; Fig. 1). COX has two isoforms, COX-1 and COX-2. COX inhibitors such as indomethacin inhibit a significant component of endothelium-dependent vascular relaxation, and gender differences in the indomethacin-sensitive component of vascular relaxation have been attributed to differences in the COX products (6). Estrogen may augment the production of COX products such as PGI₂ (41). Physiological levels of E₂ cause upregulation of COX-1 expression and PGI₂ synthesis in ovine fetal pulmonary artery and human umbilical vein endothelial cells (66). Also, E₂ causes rapid ER--mediated stimulation of PGI₂ synthesis in ovine fetal pulmonary artery endothelial cells via a Ca²⁺-dependent, but MAPK-independent, pathway (118). It has also been suggested that the COX-2 pathway plays a specific role in the rapid E₂-induced potentiation of cholinergic vasodilation in postmenopausal women (13). However, other studies have reported that indomethacin does not affect the E₂-induced relaxation in endothelium-intact coronary artery, suggesting that the release of vasodilator prostanoids may not be involved in the E₂-induced coronary relaxation (62). It has also been suggested that estrogen may modulate cross-talk between the NO synthase and COX pathways of vasodilation and that estrogen-induced increase in the NO component of endothelium-dependent dilation may be associated with a decrease in the COX component (15).

In regard to other sex hormones, some studies have shown that concomitant administration of progesterone with estrogen prevents the stimulatory effects of estrogen on PGI₂ production in cultured human umbilical vein endothelial cells (87). However, other studies have shown that progesterone may exert a direct nongenomic effect on rat aorta, which involves COX activation and increased PGI₂ production (116). On the other hand, experiments on the aorta of female rat have shown that treatment with testosterone is associated with a decrease in PGI₂ synthesis (137).

	SEX HORMONES AND EDHF

TOP ABSTRACT GENDER DIFFERENCES IN VASCULAR... SEX HORMONE RECEPTORS IN... GENOMIC EFFECTS OF SEX... NONGENOMIC EFFECTS OF SEX... SEX HORMONES AND THE... SEX HORMONES AND NO SEX HORMONES AND PGI2 SEX HORMONES AND EDHF SEX HORMONES AND ENDOTHELIUM... SEX HORMONES AND VSM... SIGNALING MECHANISMS OF VSM... SEX HORMONES AND VSM... SEX HORMONES AND PKC GRANTS REFERENCES

 
The endothelium may release other relaxing factors even during complete inhibition of the NO-cGMP and the PGI₂-cAMP pathways. Such factors have been shown to activate Ca²⁺-activated K⁺ channels (BK_Ca) and to cause hyperpolarization and relaxation of the smooth muscle and thereby designated EDHF.

The greater endothelium-mediated relaxation in females compared with males may be related to differences in the endothelium-dependent hyperpolarization of VSM (67). It has been shown that ACh-induced hyperpolarization and relaxation of mesenteric arteries are reduced in OVX female and intact male rats compared with intact female rats and that the differences in the ACh responses in OVX female compared with intact female rats are eliminated in the presence of K⁺ channel blockers such as apamin or charybdotoxin. Also, the hyperpolarizing response to ACh is improved in OVX female rats treated with E₂. These data suggest that estrogen-deficient states attenuate relaxation transduced by EDHF (81, 113).

Testosterone may also promote endothelium-mediated hyperpolarization of VSM. In aortic rings of both Wistar-Kyoto (WKY) and SHR, testosterone induces concentration-dependent relaxation (58). Testosterone-induced relaxation is reduced by denudation of endothelium in SHR, but not WKY. Indomethacin and L-NAME show little influence on testosterone-induced relaxation in both WKY and SHR aortic rings. 4-Aminopyridine, inhibitor of voltage-dependent K⁺ channels, and tetraethylammonium, inhibitor of BK_Ca, reduce testosterone-induced relaxation in SHR, but not WKY. On the other hand, glibenclamide, inhibitor of ATP-sensitive K⁺ channels, reduces testosterone-induced relaxation in both WKY and SHR aortic rings. These data suggest that in SHR aortic rings, testosterone may release endothelium-derived substances that cause hyperpolarization of the cells by a mechanism that involves voltage-dependent and BK_Ca channels. However, a significant component of testosterone-induced vasorelaxation in both WKY and SHR appears to be endothelium-independent and may involve ATP-sensitive K⁺ channels in aortic smooth muscle (58).

	SEX HORMONES AND ENDOTHELIUM-DERIVED CONTRACTING FACTORS

TOP ABSTRACT GENDER DIFFERENCES IN VASCULAR... SEX HORMONE RECEPTORS IN... GENOMIC EFFECTS OF SEX... NONGENOMIC EFFECTS OF SEX... SEX HORMONES AND THE... SEX HORMONES AND NO SEX HORMONES AND PGI2 SEX HORMONES AND EDHF SEX HORMONES AND ENDOTHELIUM... SEX HORMONES AND VSM... SIGNALING MECHANISMS OF VSM... SEX HORMONES AND VSM... SEX HORMONES AND PKC GRANTS REFERENCES

 
The gender differences in vascular tone may be related to differences in the release of or sensitivity to endothelium-derived contracting factors (EDCF) such as ET-1 and thromboxane A₂. ET-1 release from endothelial cells appears to be reduced in females and may explain the decreased vascular tone and blood pressure in female compared with male SHR (67). The gender difference in ET-1 production by endothelial cells may be related to the plasma levels of estrogen (1).

ET-1 is known to interact with ET_A and ET_B receptors. The activation of endothelial ET_B causes the release of various relaxing factors that promote VSM relaxation. On the other hand, the interaction of ET-1 with ET_A and ET_B receptors in VSM activates signaling mechanisms of smooth muscle contraction. Gender differences in the vascular responses to ET-1 have been reported in DOCA-salt hypertensive rats, with the arteries of males exhibiting marked contraction to ET-1 compared with those of females, and functional changes in ET_B receptors have been suggested as one possible mechanism (131). For example, in the mesenteric arteries of DOCA rats, the ET_B agonist IRL-1620 induces mild vasoconstriction in intact females, but marked vasoconstriction in OVX females. Estradiol or estradiol/progesterone decreases IRL-1620-induced vasoconstriction in the OVX rats. Ovariectomy is also associated with increases in ET-1 and ET_B receptor mRNA in mesenteric arteries, and treatment with estradiol or estradiol/progesterone reverses these changes. These data suggest that the ovarian hormones attenuate ET-1/ET_B receptor expression and the vascular responses in DOCA-salt hypertension (29). It has also been shown that prolonged treatment of cultured endothelial cells with estradiol inhibits basal and stimulated ET-1 expression and release in response to serum, tumor necrosis factor-, transforming growth factor-₁, ANG II, and thrombin (9, 35, 93). Also, short-term intracoronary administration of E₂ decreases ET-1 levels in coronary sinus plasma of postmenopausal women with coronary artery disease (138).

Similar to estrogen, progesterone inhibits serum- and ANG II-stimulated ET-1 synthesis and release from cultured bovine aortic endothelial cells (93). Androgens appear to have the opposite effect on ET-1 production. Studies on female-to-male transsexuals receiving large doses of testosterone have shown high plasma levels of ET-1 (100). Whether testosterone-induced increase in ET-1 production could increase the risk of hypertension in males is unclear. Although ET_A-receptor antagonists prolong survival and improve renal status in male SHR, they do not reduce the blood pressure significantly, suggesting little role of ET-1 in male SHR hypertension (132).

In addition to the gender differences in ET-1 responses, it has been shown that the release of COX-derived constricting factors such as thromboxane A₂ is more pronounced in male than in female SHR (67).

	SEX HORMONES AND VSM CONTRACTION

TOP ABSTRACT GENDER DIFFERENCES IN VASCULAR... SEX HORMONE RECEPTORS IN... GENOMIC EFFECTS OF SEX... NONGENOMIC EFFECTS OF SEX... SEX HORMONES AND THE... SEX HORMONES AND NO SEX HORMONES AND PGI2 SEX HORMONES AND EDHF SEX HORMONES AND ENDOTHELIUM... SEX HORMONES AND VSM... SIGNALING MECHANISMS OF VSM... SEX HORMONES AND VSM... SEX HORMONES AND PKC GRANTS REFERENCES

 
In addition to the nongenomic effects of sex hormones on the endothelium, rapid nongenomic effects on VSM have been described (24, 62, 64, 129; Fig. 3). For example, estrogen causes vasodilation in endothelium-denuded vessels, suggesting that the estrogen-induced inhibition of vascular tone has an endothelium-independent component that involves direct action on VSM (24, 38, 62, 64). Also, estrogen causes relaxation in endothelium-denuded rabbit, porcine, and human coronary arteries precontracted by ET-1, PGF₂, and high KCl depolarizing solution (24, 51, 64; Fig. 4). The vasodilator effects of estrogen do not appear to be mediated by the classic cytosolic-nuclear ER or stimulation of protein synthesis, but rather through a direct effect of estrogen on plasmalemmal receptors in VSM (24, 38).

View larger version (49K): [in this window] [in a new window]   Fig. 3. Genomic and nongenomic effects of estrogen in VSM. In the genomic pathway, estrogen binds to cytosolic/nuclear ER, leading to inhibition of growth factor (GF)-activated MAPK and gene transcription, and thereby inhibition of VSM growth and proliferation. In the nongenomic pathway, estrogen binds to plasma membrane ER, leading to inhibition of agonist-activated mechanisms of VSM contraction. An agonist (A) activates a specific receptor (R), stimulates membrane phospholipase (PLC), and increases the production of IP3 and diacylglycerol (DAG). IP3 stimulates Ca2+ release from the sarcoplasmic reticulum (SR). Also, the agonist stimulates Ca2+ entry through Ca2+ channels. Ca2+ binds CAM, activates myosin light chain (MLC) kinase, causes MLC phosphorylation, and initiates VSM contraction. DAG causes activation of protein kinase C (PKC). PKC could phosphorylate calponin (CaP) and/or activate a protein kinase cascade involving Raf, MAPK kinase (MEK), and MAPK, leading to phosphorylation of caldesmon (CaD) and an increase in the myofilament force sensitivity to Ca2+. Possible effects of estrogen include activation of K+ channels, leading to membrane hyperpolarization, inhibition of Ca2+ entry through Ca2+ channels, and thereby inhibition of the Ca2+-dependent MLC phosphorylation and inhibition of VSM contraction. Estrogen may also inhibit PKC and/or the MAPK pathway and thereby further inhibit VSM contraction. SRC-3, steroid receptor coactivator-3; SMP, signal-modulating protein. Interrupted arrows indicate inhibition.

View larger version (10K): [in this window] [in a new window]   Fig. 4. Effect of sex hormones on PGF2-induced contraction in porcine coronary artery. Endothelium-denuded coronary artery strips were stimulated with PGF2 (10-5 M), then treated with the vehicle ethanol (A) or with 10-5 M 17-estradiol (B), progesterone (C), or testosterone (D). [Modified from (24)].

The acute vasodilator effects of estrogen may be influenced by gender, vessel type, estrous cycle, and previous exposure to estrogen. For example, in rat aorta, E₂ causes greater relaxation in males than females (25). Among female rats, the largest E₂-induced vasodilation is seen in the tail and mesenteric arteries from females at the proestrous stage. However, the magnitude of relaxation in microvessels of estradiol-replaced OVX female rats is smaller than that of nonreplaced OVX rats, suggesting that chronic estradiol replacement may downregulate the acute nongenomic vasorelaxation effects of estrogen in small arteries of OVX rats (68).

The effects of progesterone on vascular reactivity are less clear and range between no effect, inhibition of vasorelaxation, and potent vascular relaxation (24, 63, 129). Progesterone may cause endothelium-independent relaxation of VSM, although it is smaller than that induced by estrogen (24; Fig. 4). Progesterone induces relaxation of primate, porcine, rabbit, and rat coronary arteries (24, 36, 63, 90). The vasodilator effect of progesterone in isolated VSM suggests that its benefits in hormone replacement therapy may be related to its nongenomic relaxant effects on VSM.

Some studies suggest that testosterone enhances vascular contraction either by inhibiting endothelium-dependent relaxation or by directly stimulating VSM contraction (142). For example, treatment of porcine coronary artery with nanomolar concentrations of testosterone impairs bradykinin- and A23187 [GenBank] -induced endothelium-dependent vascular relaxation. Also, testosterone enhances thromboxane A₂-induced coronary vasoconstriction in guinea pigs. Flutamide, a testosterone receptor antagonist, has been shown to cause direct vasodilation in rat vessels and flutamide-induced vascular relaxation is smaller in females compared with males, suggesting that testosterone may promote vascular contraction (2). However, other studies have shown that testosterone induces relaxation of rabbit coronary artery and aorta, rat aorta, and canine and porcine coronary artery (24, 145; Fig. 4). A significant portion of the testosterone-induced vascular relaxation appears to be endothelium independent because only small differences could be observed between the relaxation in vessels with and without endothelium. Also, inhibition of endothelium-dependent relaxation pathways such as NOS and COX may not abolish the vasorelaxing effect of testosterone (145), providing evidence that a significant component of testosterone-induced relaxation is endothelium independent and involves direct action on VSM. The testosterone-induced vasorelaxation appears to be a structurally specific effect of the androgen molecule and is enhanced in more polar analogs that have a lower permeability to the VSM cell membrane (31).

We should note that although both the endogenous presence and exogenous application of sex hormones may be associated with reduction in vascular contraction, the mechanisms of hormone-induced relaxation in isolated vascular strips or cells and the possible vasorelaxant effects of the hormone in vivo may not be identical. The acute effects of estrogen on vascular contraction in vitro are often observed at micromolar concentrations, which are several-fold higher than the physiological nanomolar concentrations observed in vivo. Although a genomic action of physiological concentrations of estrogen may underlie the reduced cell contraction in VSM of intact females, it is less likely to account for the acute inhibitory effects of exogenous micromolar concentrations of E₂ on vascular contraction. The acute vasorelaxant effects of exogenous estrogen may represent additional nongenomic effects of estrogen on the mechanisms of VSM contraction (24).

We should also note that although most of the sex hormones tested appear to cause vascular relaxation and inhibit VSM contraction, the vascular relaxant effects of estrogen significantly surpass those of progesterone or testosterone (Fig. 4). Inasmuch as the estrogen levels are greater in females compared with males, this could explain the gender differences in vascular tone and the reduced vascular contraction in females compared with males (Table 3). However, because the expression of sex hormone receptors in arterial smooth muscle may vary depending on the gender and the status of the gonads (127), the gender differences in vascular contraction may be related to the relative abundance of sex hormone receptors. This is supported by reports that females have higher levels of ERs in their arteries than males (21). The gender differences in vascular contraction could also be related to effects of sex hormones on the gene expression of the specific receptors of vasoconstrictor agonists such as ANG II (Table 3). Western blot analyses in VSM have revealed that estrogen induces a downregulation and progesterone an upregulation of the angiotensin AT₁ receptor protein. Also, E₂ decreases the AT₁ receptor mRNA half-life, whereas progesterone induces stabilization of AT₁ receptor mRNA (96). Other studies have shown that progesterone replacement in OVX monkeys decreases thromboxane A₂ receptors in coronary arteries (91). Nevertheless, the gender differences in vascular contraction may also be related to gender differences in the signaling mechanisms of VSM contraction downstream from receptor activation.

	SIGNALING MECHANISMS OF VSM CONTRACTION

TOP ABSTRACT GENDER DIFFERENCES IN VASCULAR... SEX HORMONE RECEPTORS IN... GENOMIC EFFECTS OF SEX... NONGENOMIC EFFECTS OF SEX... SEX HORMONES AND THE... SEX HORMONES AND NO SEX HORMONES AND PGI2 SEX HORMONES AND EDHF SEX HORMONES AND ENDOTHELIUM... SEX HORMONES AND VSM... SIGNALING MECHANISMS OF VSM... SEX HORMONES AND VSM... SEX HORMONES AND PKC GRANTS REFERENCES

 
It is widely accepted that VSM contraction is triggered by increases in [Ca²⁺]_i due to initial Ca²⁺ release from the sarcoplasmic reticulum and maintained Ca²⁺ entry from the extracellular space (73, 95). Also, activation of protein kinases such as myosin light chain (MLC) kinase, Rho kinase, and MAPK as well as inhibition of MLC phosphatase may contribute to smooth muscle contraction (59, 122; Fig. 3). Additionally, the interaction of an -adrenergic agonist such as Phe with its receptor is coupled to increased breakdown of plasma membrane phospholipids and increased production of diacylglycerol (DAG), which activates protein kinase C (PKC; 70). PKC is mainly cytosolic under resting conditions and undergoes translocation from the cytosolic to the particulate fraction when it is activated by DAG or phorbol esters. PKC is now known to be a family of several isoforms that have different enzyme properties, substrates, and functions and exhibit different subcellular distributions in the same blood vessel from different species and in different vessels from the same species (69, 70).

	SEX HORMONES AND VSM [CA2+]I

TOP ABSTRACT GENDER DIFFERENCES IN VASCULAR... SEX HORMONE RECEPTORS IN... GENOMIC EFFECTS OF SEX... NONGENOMIC EFFECTS OF SEX... SEX HORMONES AND THE... SEX HORMONES AND NO SEX HORMONES AND PGI2 SEX HORMONES AND EDHF SEX HORMONES AND ENDOTHELIUM... SEX HORMONES AND VSM... SIGNALING MECHANISMS OF VSM... SEX HORMONES AND VSM... SEX HORMONES AND PKC GRANTS REFERENCES

 
Because [Ca²⁺]_i is important for the initiation of smooth muscle contraction, several studies have used isolated vascular strips and smooth muscle cells from intact and gonadectomized male and female experimental animals to investigate the effect of gender and sex hormones on [Ca²⁺]_i and the Ca²⁺ mobilization mechanisms of smooth muscle contraction (25, 95, 146). Studies in isolated VSM cells have shown that the resting cell length is longer and the basal [Ca²⁺]_i is smaller in intact female compared with intact male rats, suggesting gender differences in the Ca²⁺ handling mechanisms (95). The gender differences in resting cell length and [Ca²⁺]_i appear to be related to estrogen because the cell length and [Ca²⁺]_i are greater in OVX females compared with intact females, but not different between OVX females with E₂ implants and intact females or between castrated and intact males (95; Fig. 5).

View larger version (28K): [in this window] [in a new window]   Fig. 5. Effect of Phe (10-5 M) on [Ca2+]i in aortic smooth muscle cells isolated from intact and gonadectomized, male and female Wistar-Kyoto (WKY; A) and spontaneously hypertensive rats (SHR; B), and ovariectomized (OVX) female rats with 17-estradiol implants and incubated in Hank's solution (1 mM Ca2+). Dashed lines are drawn at the smallest basal and maintained Phe-induced increase in [Ca2+]i in cells of intact females to facilitate comparison with the other groups. [Modified from (95)].

In cells incubated in the presence of external Ca²⁺, Phe causes an initial peak in [Ca²⁺]_i mainly due to Ca²⁺ release from the intracellular stores, followed by a smaller but maintained increase in [Ca²⁺]_i due to Ca²⁺ entry from the extracellular space (95; Fig. 5). In Ca²⁺-free solution, Phe causes a transient increase in smooth muscle contraction and [Ca²⁺]_i that is not different between intact and gonadectomized male and female rats, suggesting that the IP₃-mediated Ca²⁺ release is not involved in the gender differences in cell contraction and [Ca²⁺]_i (95). Also, caffeine, which stimulates the Ca²⁺-induced Ca²⁺ release mechanism, causes a small cell contraction and a transient increase in [Ca²⁺]_i that are similar in magnitude in intact and gonadectomized male and female rats, suggesting that the gender differences in cell contraction and [Ca²⁺]_i are not related to the Ca²⁺-induced Ca²⁺ release mechanism (95).

On the other hand, the maintained Phe-induced [Ca²⁺]_i in VSM cells incubated in the presence of external Ca²⁺ is greater in intact male than intact female rats, suggesting gender differences in the Ca²⁺ entry mechanism of VSM contraction. The maintained Phe-induced [Ca²⁺]_i is enhanced in OVX compared with intact females, but not different between OVX females with estrogen implants and intact females, or between castrated and intact males, suggesting that the gender differences are more likely related to estrogen than androgen (95; Fig. 5).

Membrane depolarization by high KCl mainly stimulates Ca²⁺ entry from the extracellular space. The reports that the KCl-induced smooth muscle contraction, Ca²⁺ influx, and [Ca²⁺]_i are greater in intact males than intact females further support gender differences in the Ca²⁺ entry mechanisms (25, 95). Also, the KCl-induced cell contraction and [Ca²⁺]_i are enhanced in OVX females compared with intact females, but not different between OVX females with estrogen implants and intact females, lending support to the contention that the gender differences are more likely related to endogenous estrogen. The causes of the gender differences in the Ca²⁺ entry mechanism are not clear, but may be related to the plasmalemmal density and/or the permeability of the Ca²⁺ channels depending on the presence or deficiency of endogenous estrogen. This is supported by reports that the expression of the L-type Ca²⁺ channels in cardiac muscle is substantially increased in ER-deficient mice and that the L-type Ca²⁺ current is significantly greater in coronary smooth muscle of males compared with females (11, 65).

Inasmuch as VSM contraction and [Ca²⁺]_i are often enhanced in animal models of hypertension, any gender differences in the Ca²⁺ mobilization mechanisms of VSM contraction are expected to be more apparent in hypertensive SHR than normotensive WKY rats. Aortic strips of SHR show greater vascular contraction and Ca²⁺ entry than those of WKY rats (25). Also, VSM cells of SHR show shorter resting cell length, greater basal [Ca²⁺]_i, and greater maintained Phe- and KCl-induced contraction and [Ca²⁺]_i than those of WKY rats (95; Fig. 5). Additionally, the reduction in vascular contraction, Ca²⁺ entry, and [Ca²⁺]_i in intact females or OVX females with estrogen implants compared with intact males or OVX females is greater in SHR than WKY rats, suggesting possible differences in the number of ERs or the number and permeability of the plasma membrane Ca²⁺ channels (25, 95). We should note that the gender differences in the mechanisms of Ca²⁺ mobilization into VSM could be due to a multitude of effects of sex hormones in vivo. However, E₂ causes relatively rapid relaxation of isolated vascular strips of rabbit, porcine, and human coronary artery, suggesting that it may be mediated by an effect on Ca²⁺ mobilization and/or fluxes (24; Fig. 5).

Several studies have shown that estrogen does not inhibit caffeine- or carbachol-induced smooth muscle contraction or [Ca²⁺]_i in Ca²⁺-free solution, suggesting that it does not inhibit Ca²⁺ release from the intracellular stores (24, 94). However, supraphysiological concentrations of estrogen may inhibit thromboxane A₂-induced Ca²⁺ release in porcine coronary artery (50). On the other hand, estrogen inhibits the maintained Phe-, PGF₂-, and thromboxane A₂-induced contraction, Ca²⁺ influx, and [Ca²⁺]_i, suggesting inhibition of Ca²⁺ entry from the extracellular space (24, 50, 94). Also, estrogen inhibits the high KCl-induced contraction, Ca²⁺ influx, and [Ca²⁺]_i, suggesting that it may act by inhibiting Ca²⁺ entry through voltage-gated channels (24, 40, 76, 94; Fig. 6).

View larger version (21K): [in this window] [in a new window]   Fig. 6. Effect of sex hormones on KCl-stimulated [Ca2+]i in male porcine coronary smooth muscle cells. Cells were stimulated with 51 mM KCl solution for 5 min. Cells were then treated with the vehicle ethanol (A) or with 10-7 M 17-estradiol (B), progesterone (C), or testosterone (D). [Modified from (94)].

Estrogen may inhibit Ca²⁺ entry by direct or indirect action on plasmalemmal Ca²⁺ channels. Some studies have shown that estrogen blocks Ca²⁺ channels in cultured A7r5 and aortic smooth muscle cells (146). Other studies have shown that estrogen activates BK_Ca channels in coronary smooth muscle cells, which could lead to hyperpolarization and decreased Ca²⁺ entry through voltage-gated channels (140). However, estrogen-induced vasorelaxation and inhibition of Ca²⁺ influx into VSM have been observed even in the absence of activation of K⁺ efflux, lending support to direct effects of estrogen on Ca²⁺ channels (114).

Estrogen may also decrease [Ca²⁺]_i by stimulating Ca²⁺ extrusion via plasmalemmal Ca²⁺ pump (101). However, this mechanism seems less likely because the rate of decay of caffeine- and carbachol-induced contraction and [Ca²⁺]_i transients in smooth muscle incubated in Ca²⁺-free solution, which are often used as a measure of Ca²⁺ extrusion, are not affected by estrogen (24, 94).

In contrast to estrogen, the effects of progesterone on [Ca²⁺]_i have not been clearly established. However, several studies have shown that acute application of progesterone decreases Ca²⁺ influx and [Ca²⁺]_i in rabbit and porcine coronary smooth muscle (24, 94; Fig. 6). There have also been inconsistent reports regarding the effects of testosterone on VSM [Ca²⁺]_i. However, the majority of studies suggests that testosterone has a potent vasorelaxant effect in the rabbit coronary artery and aorta and porcine coronary artery and that testosterone decreases VSM [Ca²⁺]_i by inhibiting Ca²⁺ entry from the extracellular space (24, 94, 145; Fig. 6). It has been shown that the relaxing effect of testosterone is attenuated by K⁺ channel blockers, suggesting that stimulation of K⁺ conductance through specific K⁺ channels, e.g., voltage-dependent (delayed rectifier) K⁺ channel may be involved in the inhibitory effects of testosterone on [Ca²⁺]_i (145).

The progesterone- and testosterone-induced inhibition of PGF₂-induced contraction is greater than the inhibition of the KCl-induced responses (24). These data suggest that progesterone and testosterone not only inhibit Ca²⁺ entry through voltage-gated channels, but may also inhibit additional VSM contraction mechanisms activated by PGF₂ such as PKC.

	SEX HORMONES AND PKC

TOP ABSTRACT GENDER DIFFERENCES IN VASCULAR... SEX HORMONE RECEPTORS IN... GENOMIC EFFECTS OF SEX... NONGENOMIC EFFECTS OF SEX... SEX HORMONES AND THE... SEX HORMONES AND NO SEX HORMONES AND PGI2 SEX HORMONES AND EDHF SEX HORMONES AND ENDOTHELIUM... SEX HORMONES AND VSM... SIGNALING MECHANISMS OF VSM... SEX HORMONES AND VSM... SEX HORMONES AND PKC GRANTS REFERENCES

 
Recent studies have investigated whether the gender differences in vascular contraction reflect differences in the expression/activity of PKC isoforms in VSM. Phorbol esters, which activate PKC, produce greater contraction in isolated vessels of intact male than intact female rats (69). The greater Phe- and phorbol ester-induced contraction and PKC activity in intact male compared with intact female rats have suggested gender differences in the PKC-mediated pathway of VSM contraction (69), which may be related to differences in the amount of PKC expressed in VSM and/or the sensitivity of the PKC pathway to endogenous sex hormones.

Immunoblot analysis in aortic smooth muscle of intact male WKY rat has shown significant amounts of -, -, and -PKC (Fig. 7). In the same preparation, both Phe and phorbol ester cause activation and redistribution of - and -PKC from the cytosolic to the particulate fraction. The amount of -, -, and -PKC, and the Phe- and phorbol ester-induced redistribution of - and -PKC are reduced in intact females compared with intact males, suggesting that the gender differences in vascular contraction are related, in part, to underlying changes in the amount and activity of -, -, and -PKC (69; Fig. 7).

View larger version (22K): [in this window] [in a new window]   Fig. 7. Expression of -PKC in aortic smooth muscle of intact and gonadectomized male and female WKY (open bars) and SHR rats (solid bars). Western blot analysis was performed using whole tissue homogenate of rat aorta and anti -PKC antibody. Position of the molecular mass marker is shown at right. Amount of -PKC is expressed as optical density. *SHR significantly different (P < 0.05) from WKY. #Significantly different from other WKY. Significantly different from other SHR. [Modified from (69)].

The Phe- and phorbol ester-induced contraction and PKC activity are not different between castrated and intact male rats, but greater in OVX than intact females, suggesting that the gender differences in vascular contraction and PKC activity are more likely related to estrogens than androgens. This is supported by reports that inserting E₂ implants in OVX female and castrated male rats is associated with reduction in vascular contraction and PKC activity (69).

Previous studies have shown that vascular PKC activity is augmented in the SHR rat model of enhanced vascular contraction. Also, the reduction in vascular contraction and PKC activity in intact females compared with intact males is greater in SHR than WKY. The greater reduction in vascular contraction and PKC activity in intact female SHR compared with WKY could not be explained by differences in their plasma estrogen levels and appear to be related to inherent differences in the amount of PKC isoforms expressed in VSM (69; Fig. 7).

A genomic action of estrogen on the expression of PKC isoforms in VSM might well underlie the reduction in vascular contraction and PKC activity observed in intact females compared with intact males. However, additional nongenomic effects of estrogen on the PKC molecule or its lipid cofactors or other protein kinases upstream from PKC cannot be excluded. Although a direct effect of estrogen on PKC activity has not been established, progesterone has been shown to inhibit phorbol ester-induced contraction and PKC translocation in VSM, suggesting an effect of progesterone on PKC activity (53). The progesterone-induced inhibition of PKC may be mediated by increasing cAMP levels in VSM (53).

Perspectives

It is apparent that there is an array of factors contributing to the greater incidence of cardiovascular disease in men and postmenopausal women compared with premenopausal women. One contributing factor is gender differences in the regulation of vascular tone. Numerous studies have suggested both genomic and nongenomic effects of sex hormones on the endothelium and VSM, but there are yet many unanswered questions.

One important question is related to the subtypes, distribution, and function of sex hormone receptors in vascular cells. In blood vessels of wild-type mice, estrogen attenuates vasoconstriction via an ER--mediated increase in iNOS expression. Initial studies in ER knockout mice have shown that deficiency of ER- renders the aortic wall supersensitive to relaxation by E₂, but does not change the vascular wall morphology, suggesting that ER- may not be involved in vascular structure development. Other studies have shown that ER--deficient mice develop hypertension as they age, and their blood vessels show abnormal ion channel functions (84, 147), supporting a role for ER- in the regulation of vascular function and blood pressure. However, complex tissue-specific effects of sex hormones may be mediated by the expression of heterogeneous forms of their cognate receptors. Variant estrogen, progesterone, and testosterone receptor transcripts are expressed in human vascular cells and may alter the physiological effects of estrogen, progestins, and androgens on the endothelium and VSM.

In addition to the nuclear ERs that mediate the classic transcriptional effects of estrogen, ERs may associate with the cell membrane, and a subpopulation of these membrane-bound ERs may mediate the rapid effects of estrogen. However, little is known regarding the pathways that regulate the distribution of ER between the nuclear and membrane fractions. Phosphorylation of transcription factors plays an important role in regulation of gene expression, and subcellular trafficking of specific transcription factors is regulated by phosphorylation/dephosphorylation. Steroid hormone receptors are phosphoproteins, and mutations in phosphorylation sites may affect the transactivation capacity of these transcription factors (10). Studies in human VSM cells transiently transfected with ER- have shown translocation of ER- from the membrane to the nucleus. Nuclear localization of ER- was blocked by both pharmacological and genetic inhibition of MAPK. Also, constitutive activation of MAPK resulted in nuclear translocation of ER-. These studies suggest that MAPK-mediated phosphorylation of ER- induces its nuclear localization (82).

Another question relates to the effect of sex hormones on cell growth and proliferation. Why estrogen enhances the proliferation of endothelial cells but inhibits the proliferation of VSM cells remains an enigma and should represent an important area for future studies.

The rapid vasodilator effects of estrogen have suggested other mechanisms in addition to the classic genomic pathway of steroid action, possibly involving effects on the cellular mechanisms of vascular relaxation and/or contraction. Recent evidence indicates that Ca²⁺ and K⁺ channels in VSM cells play an important role in mediating estrogen-induced relaxation of many vascular beds; however, elucidation of the signal transduction mechanisms coupling ER- and ER- activation to generation of second messengers and effector mechanisms remains an area of intense study.

Although the gender differences in vascular contraction may be related to effects of sex hormones on vascular [Ca²⁺]_i or PKC activity, other protein kinases such as MLC kinase, Rho kinase, and tyrosine kinase as well as MLC phosphatase could regulate smooth muscle contraction. Whether the expression and activity of smooth muscle protein kinases and phosphatases differ with gender and by the presence or deficiency of gonadal hormones is unclear and should be examined in future investigations.

There is considerable evidence that both female and male sex hormones affect the mechanisms of vascular contraction; however, the vascular effects of sex hormones may not be uniform. Sex hormones have different sexual effects in both sexes, and it is reasonable to believe that the vascular effects of sex hormones are different in the two sexes. Preliminary studies suggest gender differences in the effects of estrogen on the mechanisms of vascular contraction (25), a research area that should be more thoroughly examined.

Because the vascular effects of estrogen and progesterone may involve modulation of the Ca²⁺ channels, HRT may represent a natural approach to decrease the severity of certain forms of hypertension that are responsive to Ca²⁺ channel blockers. To use or not to use HRT in postmenopausal women with hypertension or coronary artery disease is still controversial. Reports from HERS, HERS2, and WHI studies do not appear to support beneficial vascular effects of HRT, particularly in elderly hypertensive women (37, 47, 74, 89, 117, 119). However, HRT may be beneficial in reducing the incidence of coronary artery disease in postmenopausal women (43, 48, 108). Also, some studies demonstrated that postmenopausal HRT is accompanied with a reduction in arterial pressure when natural hormones are used in a manner that avoids first-pass liver effects and in doses that produce hormone levels similar to those in the premenopausal state (32). Furthermore, estradiol metabolism may be an important determinant of its cardiovascular protective effects, and nonfeminizing estradiol metabolites may confer cardiovascular protection in both genders (7). Finally, compared with the role of estradiol in the regulation of vascular tone, there are sparse data on the effects of androgens and androgen receptors on the vascular control mechanisms. Whether the recently discovered effects of testosterone on the mechanisms of vascular relaxation/contraction justify its potential use in prevention of cardiovascular disease remains to be explored (107).

	GRANTS

TOP ABSTRACT GENDER DIFFERENCES IN VASCULAR... SEX HORMONE RECEPTORS IN... GENOMIC EFFECTS OF SEX... NONGENOMIC EFFECTS OF SEX... SEX HORMONES AND THE... SEX HORMONES AND NO SEX HORMONES AND PGI2 SEX HORMONES AND EDHF SEX HORMONES AND ENDOTHELIUM... SEX HORMONES AND VSM... SIGNALING MECHANISMS OF VSM... SEX HORMONES AND VSM... SEX HORMONES AND PKC GRANTS REFERENCES

 
This work was supported by grants from National Heart, Lung, and Blood Institute (HL-52696, HL-65998, and HL-70659). R. A. Khalil is an Established Investigator of the American Heart Association.

	FOOTNOTES

 

Address for reprint requests and other correspondence: R. A. Khalil, Harvard Medical School, VA Boston Healthcare-Research, 1400 VFW Parkway 3/2B123, Boston, MA 02132 (E-mail: raouf_khalil{at}hms.harvard.edu).

	REFERENCES

TOP ABSTRACT GENDER DIFFERENCES IN VASCULAR... SEX HORMONE RECEPTORS IN... GENOMIC EFFECTS OF SEX... NONGENOMIC EFFECTS OF SEX... SEX HORMONES AND THE... SEX HORMONES AND NO SEX HORMONES AND PGI2 SEX HORMONES AND EDHF SEX HORMONES AND ENDOTHELIUM... SEX HORMONES AND VSM... SIGNALING MECHANISMS OF VSM... SEX HORMONES AND VSM... SEX HORMONES AND PKC GRANTS REFERENCES

 

1. Akishita M, Kozaki K, Eto M, Yoshizumi M, Ishikawa M, Toba K, Orimo H, and Ouchi Y. Estrogen attenuates endothelin-1 production by bovine endothelial cells via estrogen receptor. Biochem Biophys Res Commun 251: 17-21, 1998.[CrossRef][Web of Science][Medline]
2. Ba ZF, Wang P, Kuebler JF, Rue LW III, Bland KI, and Chaudry IH. Flutamide induces relaxation in large and small blood vessels. Arch Surg 137: 1180-1186, 2002.[Abstract/Free Full Text]
3. Bacakova L and Kunes J. Gender differences in growth of vascular smooth muscle cells isolated from hypertensive and normotensive rats. Clin Exp Hypertens 22: 33-44, 2000.[CrossRef][Web of Science][Medline]
4. Bar J, Tepper R, Fuchs J, Pardo Y, Goldberger S, and Ovadia J. The effect of estrogen replacement therapy on platelet aggregation and adenosine triphosphate release in postmenopausal women. Obstet Gynecol 81: 261-264, 1993.[Web of Science][Medline]
5. Barbacanne MA, Rami J, Michel JB, Souchard JP, Philippe M, Besombes JP, Bayard F, and Arnal JF. Estradiol increases rat aorta endothelium-derived relaxing factor (EDRF) activity without changes in endothelial NO synthase gene expression: possible role of decreased endothelium-derived superoxide anion production. Cardiovasc Res 41: 672-681, 1999.[Abstract/Free Full Text]
6. Barber DA and Miller VM. Gender differences in endothelium-dependent relaxations do not involve NO in porcine coronary arteries. Am J Physiol Heart Circ Physiol 273: H2325-H2332, 1997.[Abstract/Free Full Text]
7. Barchiesi F, Jackson EK, Gillespie DG, Zacharia LC, Fingerle J, and Dubey RK. Methoxyestradiols mediate estradiol-induced antimitogenesis in human aortic SMCs. Hypertension 39: 874-879, 2002.[Abstract/Free Full Text]
8. Beldekas JC, Smith B, Gerstenfeld LC, Sonenshein GE, and Franzblau C. Effects of 17-estradiol on the biosynthesis of collagen in cultured bovine aortic smooth muscle cells. Biochemistry 20: 2162-2167, 1981.[CrossRef][Medline]
9. Bilsel AS, Moini H, Tetik E, Aksungar F, Kaynak B, and Ozer A. 17-Estradiol modulates endothelin-1 expression and release in human endothelial cells. Cardiovasc Res 46: 579-584, 2000.[Abstract/Free Full Text]
10. Blok LJ, de Ruiter PE, and Brinkmann AO. Androgen receptor phosphorylation. Endocr Res 22: 197-219, 1996.[Web of Science][Medline]
11. Bowles DK. Gender influences coronary L-type Ca²⁺ current and adaptation to exercise training in miniature swine. J Appl Physiol 91: 2503-2510, 2001.[Abstract/Free Full Text]
12. Brandes RP and Mugge A. Gender differences in the generation of superoxide anions in the rat aorta. Life Sci 60: 391-396, 1997.[CrossRef][Web of Science][Medline]
13. Calkin AC, Sudhir K, Honisett S, Williams MR, Dawood T, and Komesaroff PA. Rapid potentiation of endothelium-dependent vasodilation by estradiol in postmenopausal women is mediated via cyclooxygenase 2. J Clin Endocrinol Metab 87: 5072-5075, 2002.[Abstract/Free Full Text]
14. Campbell-Thompson M, Lynch IJ, and Bhardwaj B. Expression of estrogen receptor (ER) subtypes and ER isoforms in colon cancer. Cancer Res 61: 632-640, 2001.[Abstract/Free Full Text]
15. Case J and Davison CA. Estrogen alters relative contributions of nitric oxide and cyclooxygenase products to endothelium-dependent vasodilation. J Pharmacol Exp Ther 291: 524-530, 1999.[Abstract/Free Full Text]
16. Caulin-Glaser T, Garcia-Cardena G, Sarrel P, Sessa WC, and Bender JR. 17-Estradiol regulation of human endothelial cell basal nitric oxide release, independent of cytosolic Ca²⁺ mobilization. Circ Res 81: 885-892, 1997.[Abstract/Free Full Text]
17. Chambliss KL, Yuhanna IS, Anderson RG, Mendelsohn ME, and Shaul PW. ER has nongenomic action in caveolae. Mol Endocrinol 16: 938-946, 2002.[Abstract/Free Full Text]
18. Chan HY, Yao X, Tsang SY, Chan FL, Lau CW, and Huang Y. Different role of endothelium/nitric oxide in 17-estradiol- and progesterone-induced relaxation in rat arteries. Life Sci 69: 1609-1617, 2001.[CrossRef][Web of Science][Medline]
19. Chen Z, Yuhanna IS, Galcheva-Gargova Z, Karas RH, Mendelsohn ME, and Shaul PW. Estrogen receptor mediates the nongenomic activation of endothelial nitric oxide synthase by estrogen. J Clin Invest 103: 401-406, 1999.[Web of Science][Medline]
20. Chou TM, Sudhir K, Hutchison SJ, Ko E, Amidon TM, Collins P, and Chatterjee K. Testosterone induces dilation of canine coronary conductance and resistance arteries in vivo. Circulation 94: 2614-2619, 1996.[Abstract/Free Full Text]
21. Collins P, Rosano GM, Sarrel PM, Ulrich L, Adamopoulos S, Beale CM, McNeill JG, and Poole-Wilson PA. 17-Estradiol attenuates acetylcholine-induced coronary arterial constriction in women but not men with coronary heart disease. Circulation 92: 24-30, 1995.[Abstract/Free Full Text]
22. Costarella CE, Stallone JN, Rutecki GW, and Whittier FC. Testosterone causes direct relaxation of rat thoracic aorta. J Pharmacol Exp Ther 277: 34-39, 1996.[Abstract/Free Full Text]
23. Cox DA and Cohen ML. Influence of gender on vasomotor effects of oxidized low-density lipoprotein in porcine coronary arteries. Am J Physiol Heart Circ Physiol 272: H2577-H2583, 1997.[Abstract/Free Full Text]
24. Crews JK and Khalil RA. Antagonistic effects of 17-estradiol, progesterone and testosterone on Ca²⁺ entry mechanisms of coronary vasoconstriction. Arterioscler Thromb Vasc Biol 19: 1034-1040, 1999.[Abstract/Free Full Text]
25. Crews JK and Khalil RA. Gender-specific inhibition of Ca²⁺ entry mechanisms of arterial vasoconstriction by sex hormones. Clin Exp Pharmacol Physiol 26: 707-715, 1999.[CrossRef][Web of Science][Medline]
26. Dan P, Cheung JC, Scriven DR, and Moore ED. Epitope-dependent localization of estrogen receptor-, but not -, in en face arterial endothelium. Am J Physiol Heart Circ Physiol 284: H1295-H1306, 2003.[Abstract/Free Full Text]
27. Darblade B, Pendaries C, Krust A, Dupont S, Fouque MJ, Rami J, Chambon P, Bayard F, and Arnal JF. Estradiol alters nitric oxide production in the mouse aorta through the -, but not -, estrogen receptor. Circ Res 90: 413-419, 2002.[Abstract/Free Full Text]
28. Darkow DJ, Lu L, and White RE. Estrogen relaxation of coronary artery smooth muscle is mediated by nitric oxide and cGMP. Am J Physiol Heart Circ Physiol 272: H2765-H2773, 1997.[Abstract/Free Full Text]
29. David FL, Carvalho MH, Cobra AL, Nigro D, Fortes ZB, Reboucas NA, and Tostes RC. Ovarian hormones modulate endothelin-1 vascular reactivity and mRNA expression in DOCA-salt hypertensive rats. Hypertension 38: 692-696, 2001.[Abstract/Free Full Text]
30. Davis MJ and Hill MA. Signaling mechanisms underlying the vascular myogenic response. Physiol Rev 79: 387-423, 1999.[Abstract/Free Full Text]
31. Ding AQ and Stallone JN. Testosterone-induced relaxation of rat aorta is androgen structure specific and involves K⁺ channel activation. J Appl Physiol 91: 2742-2750, 2001.[Abstract/Free Full Text]
32. Dourakis SP and Tolis G. Sex hormonal preparations and the liver. Eur J Contracept Reprod Health Care 3: 7-16, 1998.[Medline]
33. Dubey RK, Gillespie DG, Imthurn B, Rosselli M, Jackson EK, and Keller PJ. Phytoestrogens inhibit growth and MAP kinase activity in human aortic smooth muscle cells. Hypertension 33: 177-182, 1999.[Abstract/Free Full Text]
34. Dubey RK, Gillespie DG, Mi Z, Rosselli M, Keller PJ, and Jackson EK. Estradiol inhibits smooth muscle cell growth in part by activating the cAMP-adenosine pathway. Hypertension 35: 262-266, 2000.[Abstract/Free Full Text]
35. Dubey RK, Jackson EK, Keller PJ, Imthurn B, and Rosselli M. Estradiol metabolites inhibit endothelin synthesis by an estrogen receptor-independent mechanism. Hypertension 37: 640-644, 2001.[Abstract/Free Full Text]
36. English KM, Jones RD, Jones TH, Morice AH, and Channer KS. Gender differences in the vasomotor effects of different steroid hormones in rat pulmonary and coronary arteries. Horm Metab Res 33: 645-652, 2001.[CrossRef][Web of Science][Medline]
37. Enstrom I, Lidfeldt J, Lindholm LH, Nerbrand C, Pennert K, and Samsioe G. Does blood pressure differ between users and non-users of hormone replacement therapy? The Women's Health In the Lund Area (WHILA) Study. Blood Press 11: 240-243, 2002.[CrossRef][Web of Science][Medline]
38. Farhat MY, Lavigne MC, and Ramwell PW. The vascular protective effects of estrogen. FASEB J 10: 615-624, 1996.[Abstract]
39. Forte P, Kneale BJ, Milne E, Chowienczyk PJ, Johnston A, Benjamin N, and Ritter JM. Evidence for a difference in nitric oxide biosynthesis between healthy women and men. Hypertension 32: 730-734, 1998.[Abstract/Free Full Text]
40. Freay AD, Curtis SW, Korach KS, and Rubanyi GM. Mechanism of vascular smooth muscle relaxation by estrogen in depolarized rat and mouse aorta. Role of nuclear estrogen receptor and Ca²⁺ uptake. Circ Res 81: 242-248, 1997.[Abstract/Free Full Text]
41. Geary GG, Krause DN, and Duckles SP. Estrogen reduces mouse cerebral artery tone through endothelial NOS- and cyclooxygenase-dependent mechanisms. Am J Physiol Heart Circ Physiol 279: H511-H519, 2000.[Abstract/Free Full Text]
42. Geraldes P, Sirois MG, Bernatchez PN, and Tanguay JF. Estrogen regulation of endothelial and smooth muscle cell migration and proliferation: role of p38 and p42/44 mitogen-activated protein kinase. Arterioscler Thromb Vasc Biol 22: 1585-1590, 2002.[Abstract/Free Full Text]
43. Gerhard M and Ganz P. How do we explain the clinical benefits of estrogen from bedside to bench. Circulation 92: 5-8, 1995.[Free Full Text]
44. Gerhard M, Walsh BW, Tawakol A, Haley EA, Creager SJ, Seely EW, Ganz P, and Creager MA. Estradiol therapy combined with progesterone and endothelium-dependent vasodilation in postmenopausal women. Circulation 98: 1158-1163, 1998.[Abstract/Free Full Text]
45. Gilligan DM, Badar DM, Panza JA, Quyyumi AA, and Cannon RO III. Acute vascular effects of estrogen in postmenopausal women. Circulation 90: 786-791, 1994.[Abstract/Free Full Text]
46. Gragasin FS, Xu Y, Arenas IA, Kainth N, and Davidge ST. Estrogen reduces angiotensin II-induced nitric oxide synthase and NAD(P)H oxidase expression in endothelial cells. Arterioscler Thromb Vasc Biol 23: 38-44, 2003.[Abstract/Free Full Text]
47. Grimes DA and Lobo RA. Perspectives on the Women's Health Initiative trial of hormone replacement therapy. Obstet Gynecol 100: 1344-1353, 2002.[CrossRef][Web of Science][Medline]
48. Grodstein F, Stampfer MJ, Manson JE, Colditz GA, Willett WC, Rosner B, Speizer FE, and Hennekens CH. Postmenopausal estrogen and progestin use and the risk of cardiovascular disease. N Engl J Med 335: 453-461, 1996.[Abstract/Free Full Text]
49. Guiochon-Mantel A. Regulation of the differentiation and proliferation of smooth muscle cells by the sex hormones. Rev Mal Respir 17: 604-608, 2000.[Web of Science][Medline]
50. Han SZ, Karaki H, Ouchi Y, Akishita M, and Orimo H. 17-Estradiol inhibits Ca²⁺ influx and Ca²⁺ release induced by thromboxane A₂ in porcine coronary artery. Circulation 91: 2619-2626, 1995.[Abstract/Free Full Text]
51. Harder DR and Coulson PB. Estrogen receptors and effects on membrane electrical properties of coronary vascular smooth muscle. J Cell Physiol 100: 375-382, 1979.[CrossRef][Web of Science][Medline]
52. Haynes MP, Sinha D, Russell KS, Collinge M, Fulton D, Morales-Ruiz M, Sessa WC, and Bender JR. Membrane estrogen receptor engagement activates endothelial nitric oxide synthase via the PI3-kinase-Akt pathway in human endothelial cells. Circ Res 87: 677-682, 2000.[Abstract/Free Full Text]
53. Herkert O, Kuhl H, Busse R, and Schini-Kerth VB. The progestin levonorgestrel induces endothelium-independent relaxation of rabbit jugular vein via inhibition of calcium entry and protein kinase C: role of cyclic AMP. Br J Pharmacol 130: 1911-1918, 2000.[CrossRef][Web of Science][Medline]
54. Hernandez I, Delgado JL, Diaz J, Quesada T, Teruel MJ, Llanos MC, and Carbonell LF. 17-Estradiol prevents oxidative stress and decreases blood pressure in ovariectomized rats. Am J Physiol Regul Integr Comp Physiol 279: R1599-R1605, 2000.[Abstract/Free Full Text]
55. Higashiura K, Mathur RS, and Halushka PV. Gender-related differences in androgen regulation of thromboxane A₂ receptors in rat aortic smooth-muscle cells. J Cardiovasc Pharmacol 29: 311-315, 1997.[CrossRef][Web of Science][Medline]
56. Hisamoto K, Ohmichi M, Kurachi H, Hayakawa J, Kanda Y, Nishio Y, Adachi K, Tasaka K, Miyoshi E, Fujiwara N, Taniguchi N, and Murata Y. Estrogen induces the Akt-dependent activation of endothelial nitric-oxide synthase in vascular endothelial cells. J Biol Chem 276: 3459-3467, 2001.[Abstract/Free Full Text]
57. Hodges YK, Tung L, Yan XD, Graham JD, Horwitz KB, and Horwitz LD. Estrogen receptors and : prevalence of estrogen receptor mRNA in human vascular smooth muscle and transcriptional effects. Circulation 101: 1792-1798, 2000.[Abstract/Free Full Text]
58. Honda H, Unemoto T, and Kogo H. Different mechanisms for testosterone-induced relaxation of aorta between normotensive and spontaneously hypertensive rats. Hypertension 34: 1232-1236, 1999.[Abstract/Free Full Text]
59. Horowitz A, Menice CB, Laporte R, and Morgan KG. Mechanisms of smooth muscle contraction. Physiol Rev 76: 967-1003, 1996.[Abstract/Free Full Text]
60. Horwitz KB and Horwitz LD. Canine vascular tissues are targets for androgens, estrogens, progestins, and glucocorticoids. J Clin Invest 69: 750-758, 1982.[Web of Science][Medline]
61. Iliescu R, Campos LA, Schlegel WP, Morano I, Baltatu O, and Bader M. Androgen receptor independent cardiovascular action of the antiandrogen flutamide. J Mol Med 81: 420-427, 2003.[CrossRef][Web of Science][Medline]
62. Jiang C, Sarrel PM, Lindsay DC, Poole-Wilson PA, and Collins P. Endothelium-independent relaxation of rabbit coronary artery by 17-estradiol in vitro. Br J Pharmacol 104: 1033-1037, 1991.[Web of Science][Medline]
63. Jiang C, Sarrel PM, Lindsay DC, Poole-Wilson PA, and Collins P. Progesterone induces endothelium-independent relaxation of rabbit coronary artery in vitro. Eur J Pharmacol 211: 163-167, 1992.[CrossRef][Web of Science][Medline]
64. Jiang C, Sarrel PM, Poole-Wilson PA, and Collins P. Acute effect of 17-estradiol on rabbit coronary artery contractile responses to endothelin-1. Am J Physiol Heart Circ Physiol 263: H271-H275, 1992.[Abstract/Free Full Text]
65. Johnson BD, Zheng W, Korach KS, Scheuer T, Catterall WA, and Rubanyi GM. Increased expression of the cardiac L-type calcium channel in estrogen receptor-deficient mice. J Gen Physiol 110: 135-140, 1997.[Abstract/Free Full Text]
66. Jun SS, Chen Z, Pace MC, and Shaul PW. Estrogen upregulates cyclooxygenase-1 gene expression in ovine fetal pulmonary artery endothelium. J Clin Invest 102: 176-183, 1998.[Web of Science][Medline]
67. Kahonen M, Tolvanen JP, Sallinen K, Wu X, and Porsti I. Influence of gender on control of arterial tone in experimental hypertension. Am J Physiol Heart Circ Physiol 275: H15-H22, 1998.[Abstract/Free Full Text]
68. Kakucs R, Varbiro S, Nadasy GL, Monos E, and Szekacs B. Acute, nongenomic vasodilatory action of estradiol is attenuated by chronic estradiol treatment. Exp Biol Med (Maywood) 226: 538-542, 2001.[Abstract/Free Full Text]
69. Kanashiro CA and Khalil RA. Gender-related distinctions in protein kinase C activity in rat vascular smooth muscle. Am J Physiol Cell Physiol 280: C34-C45, 2001.[Abstract/Free Full Text]
70. Kanashiro CA and Khalil RA. Signal transduction by protein kinase C in mammalian cells. Clin Exp Pharmacol Physiol 25: 974-985, 1998.[Web of Science][Medline]
71. Kauser K and Rubanyi GM. Gender difference in bioassayable endothelium-derived nitric oxide from isolated rat aortae. Am J Physiol Heart Circ Physiol 267: H2311-H2317, 1994.[Abstract/Free Full Text]
72. Kauser K and Rubanyi GM. Gender difference in endothelial dysfunction in the aorta of spontaneously hypertensive rats. Hypertension 25: 517-523, 1995.[Abstract/Free Full Text]
73. Khalil RA and van Breemen C. Mechanisms of calcium mobilization and homeostasis in vascular smooth muscle and their relevance to hypertension. In: Hypertension: Pathophysiology, Diagnosis, and Management, edited by Laragh JH and Brenner BM. New York: Raven, 1995, p. 523-540.
74. Khan NS and Malhotra S. Effect of hormone replacement therapy on cardiovascular disease: current opinion. Exp Opin Pharmacother 4: 667-674, 2003.[CrossRef][Web of Science][Medline]
75. Kim-Schulze S, McGowan KA, Hubchak SC, Cid MC, Martin MB, Kleinman HK, Greene GL, and Schnaper HW. Expression of an estrogen receptor by human coronary artery and umbilical vein endothelial cells. Circulation 94: 1402-1407, 1996.[Abstract/Free Full Text]
76. Kitazawa T, Hamada E, Kitazawa K, and Gaznabi AK. Non-genomic mechanism of 17-oestradiol-induced inhibition of contraction in mammalian vascular smooth muscle. J Physiol 499: 497-511, 1997.[Abstract/Free Full Text]
77. Kneale BJ, Chowienczyk PJ, Brett SE, Coltart DJ, and Ritter JM. Gender differences in sensitivity to adrenergic agonists of forearm resistance vasculature. J Am Coll Cardiol 36: 1233-1238, 2000.[Abstract/Free Full Text]
78. Knot HJ, Lounsbury KM, Brayden JE, and Nelson MT. Gender differences in coronary artery diameter reflect changes in both endothelial Ca²⁺ and ecNOS activity. Am J Physiol Heart Circ Physiol 276: H961-H969, 1999.[Abstract/Free Full Text]
79. Kos M, Denger S, Reid G, and Gannon F. Upstream open reading frames regulate the translation of the multiple mRNA variants of the estrogen receptor . J Biol Chem 277: 37131-37138, 2002.[Abstract/Free Full Text]
80. Landers JP and Spelsberg TC. New concepts in steroid hormone action: transcription factors, proto-oncogenes, and the cascade model for steroid regulation of gene expression. Crit Rev Eukaryot Gene Expr 2: 19-63, 1992.[Medline]
81. Liu MY, Hattori Y, Fukao M, Sato A, Sakuma I, and Kanno M. Alterations in EDHF-mediated hyperpolarization and relaxation in mesenteric arteries of female rats in long-term deficiency of oestrogen and during oestrus cycle. Br J Pharmacol 132: 1035-1046, 2001.[CrossRef][Web of Science][Medline]
82. Lu Q, Ebling H, Mittler J, Baur WE, and Karas RH. MAP kinase mediates growth factor-induced nuclear translocation of estrogen receptor . FEBS Lett 516: 1-8, 2002.[CrossRef][Web of Science][Medline]
83. MacRitchie AN, Jun SS, Chen Z, German Z, Yuhanna IS, Sherman TS, and Shaul PW. Estrogen upregulates endothelial nitric oxide synthase gene expression in fetal pulmonary artery endothelium. Circ Res 81: 355-362, 1997.[Abstract/Free Full Text]
84. Mendelsohn ME. Genomic and nongenomic effects of estrogen in the vasculature. Am J Cardiol 90: 3F-6F, 2002.[CrossRef][Web of Science][Medline]
85. Meyer MC, Cummings K, and Osol G. Estrogen replacement attenuates resistance artery adrenergic sensitivity via endothelial vasodilators. Am J Physiol Heart Circ Physiol 272: H2264-H2270, 1997.[Abstract/Free Full Text]
86. Michel T. Targeting and translocation of endothelial nitric oxide synthase. Braz J Med Biol Res 32: 1361-1366, 1999.[Web of Science][Medline]
87. Mikkola T, Viinikka L, and Ylikorkala O. Administration of transdermal estrogen without progestin increases the capacity of plasma and serum to stimulate prostacyclin production in human vascular endothelial cells. Fertil Steril 73: 72-74, 2000.[CrossRef][Web of Science][Medline]
88. Miller VM and Vanhoutte PM. Progesterone and modulation of endothelium-dependent responses in canine coronary arteries. Am J Physiol Regul Integr Comp Physiol 261: R1022-R1027, 1991.[Abstract/Free Full Text]
89. Mills PJ, Farag NH, Matthews S, Nelesen RA, Berry CC, and Dimsdale JE. Hormone replacement therapy does not affect 24-h ambulatory blood pressure in healthy non-smoking postmenopausal women. Blood Press Monit 8: 57-61, 2003.[CrossRef][Web of Science][Medline]
90. Minshall RD, Pavcnik D, Browne DL, and Hermsmeyer K. Nongenomic vasodilator action of progesterone on primate coronary arteries. J Appl Physiol 92: 701-708, 2002.[Abstract/Free Full Text]
91. Minshall RD, Pavcnik D, Halushka PV, and Hermsmeyer K. Progesterone regulation of vascular thromboxane A₂ receptors in rhesus monkeys. Am J Physiol Heart Circ Physiol 281: H1498-H1507, 2001.[Abstract/Free Full Text]
92. Molinari C, Battaglia A, Grossini E, Mary DA, Stoker JB, Surico N, and Vacca G. The effect of progesterone on coronary blood flow in anaesthetized pigs. Exp Physiol 86: 101-108, 2001.[Abstract]
93. Morey AK, Razandi M, Pedram A, Hu RM, Prins BA, and Levin ER. Oestrogen and progesterone inhibit the stimulated production of endothelin-1. Biochem J 330: 1097-1105, 1998.[Web of Science][Medline]
94. Murphy JG and Khalil RA. Decreased [Ca²⁺]_i during inhibition of coronary smooth muscle contraction by 17-estradiol, progesterone, and testosterone. J Pharmacol Exp Ther 291: 44-52, 1999.[Abstract/Free Full Text]
95. Murphy JG and Khalil RA. Gender-specific reduction in contractility and [Ca²⁺]_i in vascular smooth muscle cells of female rat. Am J Physiol Cell Physiol 278: C834-C844, 2000.[Abstract/Free Full Text]
96. Nickenig G, Strehlow K, Wassmann S, Baumer AT, Albory K, Sauer H, and Bohm M. Differential effects of estrogen and progesterone on AT₁ receptor gene expression in vascular smooth muscle cells. Circulation 102: 1828-1833, 2000.[Abstract/Free Full Text]
97. Nisolle M, Gillerot S, Casanas-Roux F, Squifflet J, Berliere M, and Donnez J. Immunohistochemical study of the proliferation index, oestrogen receptors and progesterone receptors A and B in leiomyomata and normal myometrium during the menstrual cycle and under gonadotrophin-releasing hormone agonist therapy. Hum Reprod 14: 2844-2850, 1999.[Abstract/Free Full Text]
98. Pare G, Krust A, Karas RH, Dupont S, Aronovitz M, Chambon P, and Mendelsohn ME. Estrogen receptor- mediates the protective effects of estrogen against vascular injury. Circ Res 90: 1087-1092, 2002.[Abstract/Free Full Text]
99. Pieber D, Allport VC, Hills F, Johnson M, and Bennett PR. Interactions between progesterone receptor isoforms in myometrial cells in human labour. Mol Hum Reprod 7: 875-879, 2001.[Abstract/Free Full Text]
100. Polderman KH, Stehouwer CD, van Kamp GJ, Dekker GA, Verheugt FW, and Gooren LJ. Influence of sex hormones on plasma endothelin levels. Ann Intern Med 118: 429-432, 1993.[Abstract/Free Full Text]
101. Prakash YS, Togaibayeva AA, Kannan MS, Miller VM, Fitzpatrick LA, and Sieck GC. Estrogen increases Ca²⁺ efflux from female porcine coronary arterial smooth muscle. Am J Physiol Heart Circ Physiol 276: H926-H934, 1999.[Abstract/Free Full Text]
102. Rahimian R, Wang X, and van Breemen C. Gender difference in the basal intracellular Ca²⁺ concentration in rat valvular endothelial cells. Biochem Biophys Res Commun 248: 916-919, 1998.[CrossRef][Web of Science][Medline]
103. Razandi M, Oh P, Pedram A, Schnitzer J, and Levin ER. ERs associate with and regulate the production of caveolin: implications for signaling and cellular actions. Mol Endocrinol 16: 100-115, 2002.[Abstract/Free Full Text]
104. Reckelhoff JF, Zhang H, and Srivastava K. Gender differences in development of hypertension in spontaneously hypertensive rats: role of the renin-angiotensin system. Hypertension 35: 480-383, 2000.[Abstract/Free Full Text]
105. Reckelhoff JF. Gender differences in the regulation of blood pressure. Hypertension 37: 1199-1208, 2001.[Abstract/Free Full Text]
106. Rifici VA and Khachadurian AK. The inhibition of low-density lipoprotein oxidation by 17- estradiol. Metabolism 41: 1110-1114, 1992.[CrossRef][Web of Science][Medline]
107. Rosano GM, Leonardo F, Pagnotta P, Pelliccia F, Panina G, Cerquetani E, della Monica PL, Bonfigli B, Volpe M, and Chierchia SL. Acute anti-ischemic effect of testosterone in men with coronary artery disease. Circulation 99: 1666-1670, 1999.[Abstract/Free Full Text]
108. Rosano GM, Sarrel PM, Poole-Wilson PA, and Collins P. Beneficial effect of oestrogen on exercise-induced myocardial ischaemia in women with coronary artery disease. Lancet 342: 133-136, 1993.[CrossRef][Web of Science][Medline]
109. Rubanyi GM, Freay AD, Kauser K, Sukovich D, Burton G, Lubahn DB, Couse JF, Curtis SW, and Korach KS. Vascular estrogen receptors and endothelium-derived nitric oxide production in the mouse aorta. Gender difference and effect of estrogen receptor gene disruption. J Clin Invest 99: 2429-2437, 1997.[Web of Science][Medline]
110. Rubio-Gayosso I, Garcia-Ramirez O, Gutierrez-Serdan R, Guevara-Balcazar G, Munoz-Garcia O, Morato-Cartajena T, Zamora-Garza M, and Ceballos-Reyes G. Testosterone inhibits bradykinin-induced intracellular calcium kinetics in rat aortic endothelial cells in culture. Steroids 67: 393-397, 2002.[CrossRef][Web of Science][Medline]
111. Rupnow HL, Phernetton TM, Shaw CE, Modrick ML, Bird IM, and Magness RR. Endothelial vasodilator production by uterine and systemic arteries. VII Estrogen and progesterone effects on eNOS. Am J Physiol Heart Circ Physiol 280: H1699-H1705, 2001.[Abstract/Free Full Text]
112. Russell KS, Haynes MP, Sinha D, Clerisme E, and Bender JR. Human vascular endothelial cells contain membrane binding sites for estradiol, which mediate rapid intracellular signaling. Proc Natl Acad Sci USA 97: 5930-5935, 2000.[Abstract/Free Full Text]
113. Sakuma I, Liu MY, Sato A, Hayashi T, Iguchi A, Kitabatake A, and Hattori Y. Endothelium-dependent hyperpolarization and relaxation in mesenteric arteries of middle-aged rats: influence of oestrogen. Br J Pharmacol 135: 48-54, 2002.[CrossRef][Web of Science][Medline]
114. Salom JB, Burguete MC, Perez-Asensio FJ, Torregrosa G, and Alborch E. Relaxant effects of 17-estradiol in cerebral arteries through Ca²⁺ entry inhibition. J Cereb Blood Flow Metab 21: 422-429, 2001.[CrossRef][Web of Science][Medline]
115. Scobie GA, Macpherson S, Millar MR, Groome NP, Romana PG, and Saunders PT. Human oestrogen receptors: differential expression of ER alpha and beta and the identification of ER beta variants. Steroids 67: 985-992, 2002.[CrossRef][Web of Science][Medline]
116. Selles J, Polini N, Alvarez C, and Massheimer V. Nongenomic action of progesterone in rat aorta: role of nitric oxide and prostaglandins. Cell Signal 14: 431-436, 2002.[CrossRef][Web of Science][Medline]
117. Shah SH and Alexander KP. Hormone replacement therapy for primary and secondary prevention of heart disease. Curr Treat Options Cardiovasc Med 5: 25-33, 2003.[Medline]
118. Sherman TS, Chambliss KL, Gibson LL, Pace MC, Mendelsohn ME, Pfister SL, and Shaul PW. Estrogen acutely activates prostacyclin synthesis in ovine fetal pulmonary artery endothelium. Am J Respir Cell Mol Biol 26: 610-616, 2002.[Abstract/Free Full Text]
119. Simon JA, Hsia J, Cauley JA, Richards C, Harris F, Fong J, Barrett-Connor E, and Hulley SB. Postmenopausal hormone therapy and risk of stroke: The Heart and Estrogen-Progestin Replacement Study (HERS). Circulation 103: 638-642, 2001.[Abstract/Free Full Text]
120. Simoncini T, Mannella P, Fornari L, Varone G, Caruso A, and Genazzani AR. Dehydroepiandrosterone modulates endothelial nitric oxide synthesis via direct genomic and nongenomic mechanisms. Endocrinology 144: 3449-3455, 2003.[Abstract/Free Full Text]
121. Somjen D, Kohen F, Jaffe A, Amir-Zaltsman Y, Knoll E, and Stern N. Effects of gonadal steroids and their antagonists on DNA synthesis in human vascular cells. Hypertension 32: 39-45, 1998.[Abstract/Free Full Text]
122. Somlyo AP and Somlyo AV. Signal transduction by G-proteins, rhokinase and protein phosphatase to smooth muscle and non-muscle myosin II. J Physiol 522: 177-185, 2000.[Abstract/Free Full Text]
123. Stallone JN, Crofton JT, and Share L. Sexual dimorphism in vasopressin-induced contraction of rat aorta. Am J Physiol Heart Circ Physiol 260: H453-H458, 1991.[Abstract/Free Full Text]
124. Stefano GB, Prevot V, Beauvillain JC, Cadet P, Fimiani C, Welters I, Fricchione GL, Breton C, Lassalle P, Salzet M, and Bilfinger TV. Cell-surface estrogen receptors mediate calcium-dependent nitric oxide release in human endothelia. Circulation 101: 1594-1597, 2000.[Abstract/Free Full Text]
125. Sumi D, Hayashi T, Jayachandran M, and Iguchi A. Estrogen prevents destabilization of endothelial nitric oxide synthase mRNA induced by tumor necrosis factor through estrogen receptor mediated system. Life Sci 69: 1651-1660, 2001.[CrossRef][Web of Science][Medline]
126. Takeda-Matsubara Y, Nakagami H, Iwai M, Cui TX, Shiuchi T, Akishita M, Nahmias C, Ito M, and Horiuchi M. Estrogen activates phosphatases and antagonizes growth-promoting effect of angiotensin II. Hypertension 39: 41-45, 2002.[Abstract/Free Full Text]
127. Tamaya T, Wada K, Nakagawa M, Misao R, Itoh T, Imai A, and Mori H. Sexual dimorphism of binding sites of testosterone and dihydrotestosterone in rabbit model. Comp Biochem Physiol 105A: 745-749, 1993.
128. Tan E, Gurjar MV, Sharma RV, and Bhalla RC. Estrogen receptor- gene transfer into bovine aortic endothelial cells induces eNOS gene expression and inhibits cell migration. Cardiovasc Res 43: 788-797, 1999.[Abstract/Free Full Text]
129. Thompson J and Khalil RA. Gender differences in the regulation of vascular tone. Clin Exp Pharmacol Physiol 30: 90-105, 2003.[CrossRef]
130. Thompson LP, Pinkas G, and Weiner CP. Chronic 17-estradiol replacement increases nitric oxide-mediated vasodilation of guinea pig coronary microcirculation. Circulation 102: 445-451, 2000.[Abstract/Free Full Text]
131. Tostes RC, David FL, Carvalho MH, Nigro D, Scivoletto R, and Fortes ZB. Gender differences in vascular reactivity to endothelin-1 in deoxycorticosterone-salt hypertensive rats. J Cardiovasc Pharmacol 36: S99-S101, 2000.[Web of Science][Medline]
132. Touyz RM, Turgeon A, and Schiffrin EL. Endothelin-A-receptor blockade improves renal function and doubles the lifespan of stroke-prone spontaneously hypertensive rats. J Cardiovasc Pharmacol 36: S300-S304, 2000.[Web of Science][Medline]
133. Tschugguel W, Stonek F, Zhegu Z, Dietrich W, Schneeberger C, Stimpfl T, Waldhoer T, Vycudilik W, and Huber JC. Estrogen increases endothelial carbon monoxide, heme oxygenase 2, and carbon monoxide-derived cGMP by a receptor-mediated system. J Clin Endocrinol Metab 86: 3833-3839, 2001.[Abstract/Free Full Text]
134. Van der Mooren MJ, Mijatovic V, van Baal WM, and Stehouwer CD. Hormone replacement therapy in postmenopausal women with specific risk factors for coronary artery disease. Maturitas 30: 27-36, 1998.[CrossRef][Web of Science][Medline]
135. Vazquez F, Rodriguez-Manzaneque JC, Lydon JP, Edwards DP, O'Malley BW, and Iruela-Arispe ML. Progesterone regulates proliferation of endothelial cells. J Biol Chem 274: 2185-2192, 1999.[Abstract/Free Full Text]
136. Wagner AH, Schroeter MR, and Hecker M. 17-Estradiol inhibition of NADPH oxidase expression in human endothelial cells. FASEB J 15: 2121-2130, 2001.[Abstract/Free Full Text]
137. Wakasugi M, Noguchi T, Kazama YI, Kanemaru Y, and Onaya T. The effects of sex hormones on the synthesis of prostacyclin (PGI2) by vascular tissues. Prostaglandins 37: 401-410, 1989.[CrossRef][Web of Science][Medline]
138. Webb CM, Ghatei MA, McNeill JG, and Collins P. 17-Estradiol decreases endothelin-1 levels in the coronary circulation of postmenopausal women with coronary artery disease. Circulation 102: 1617-1622, 2000.[Abstract/Free Full Text]
139. Wellman GC, Bonev AD, Nelson MT, and Brayden JE. Gender differences in coronary artery diameter involve estrogen, nitric oxide, and Ca²⁺-dependent K⁺ channels. Circ Res 79: 1024-1030, 1996.[Abstract/Free Full Text]
140. White RE, Darkow DJ, and Lang JLF. Estrogen relaxes coronary arteries by opening BK_Ca channels through a cGMP-dependent mechanism. Circ Res 77: 936-942, 1995.[Abstract/Free Full Text]
141. Wilcox JN, Subramanian RR, Sundell CL, Tracey WR, Pollock JS, Harrison DG, and Marsden PA. Expression of multiple isoforms of nitric oxide synthase in normal and atherosclerotic vessels. Arterioscler Thromb Vasc Biol 17: 2479-2488, 1997.[Abstract/Free Full Text]
142. Wynne FL and Khalil RA. Testosterone and coronary vascular tone: implications in coronary artery disease. J Endocrinol Invest 26: 181-186, 2003.[Web of Science][Medline]
143. Yang S, Bae L, and Zhang L. Estrogen increases eNOS and NOx release in human coronary artery endothelium. J Cardiovasc Pharmacol 36: 242-247, 2000.[CrossRef][Web of Science][Medline]
144. Yuan Y, Liao L, Tulis DA, and Xu J. Steroid receptor coactivator-3 is required for inhibition of neointima formation by estrogen. Circulation 105: 2653-2659, 2002.[Abstract/Free Full Text]
145. Yue P, Chatterjee K, Beale C, Poole-Wilson PA, and Collins P. Testosterone relaxes rabbit coronary arteries and aorta. Circulation 91: 1154-1160, 1995.[Abstract/Free Full Text]
146. Zhang F, Ram JL, Standley PR, Sowers JR. 17-Estradiol attenuates voltage-dependent Ca²⁺ currents in A7r5 vascular smooth muscle cell line. Am J Physiol Cell Physiol 266: C975-C980, 1994.[Abstract/Free Full Text]
147. Zhu Y, Bian Z, Lu P, Karas RH, Bao L, Cox D, Hodgin J, Shaul PW, Thoren P, Smithies O, Gustafsson JA, and Mendelsohn ME. Abnormal vascular function and hypertension in mice deficient in estrogen receptor . Science 295: 505-508, 2002.[Abstract/Free Full Text]

This article has been cited by other articles:

				A. Aversa, R. Bruzziches, D. Francomano, M. Natali, and A. Lenzi Testosterone and phosphodiesterase type-5 inhibitors: new strategy for preventing endothelial damage in internal and sexual medicine? Therapeutic Advances in Urology, October 1, 2009; 1(4): 179 - 197. [Abstract] [PDF]

				A. O. Robb, N. L. Mills, J. N. Din, I. B.J. Smith, F. Paterson, D. E. Newby, and F. C. Denison Influence of the Menstrual Cycle, Pregnancy, and Preeclampsia on Arterial Stiffness Hypertension, June 1, 2009; 53(6): 952 - 958. [Abstract] [Full Text] [PDF]

				Z. Wang, Z. Huang, G. Lu, L. Lin, and M. Ferrari Hypoxia during pregnancy in rats leads to early morphological changes of atherosclerosis in adult offspring Am J Physiol Heart Circ Physiol, May 1, 2009; 296(5): H1321 - H1328. [Abstract] [Full Text] [PDF]

				G.-F. Qiao, B.-Y. Li, Y.-J. Lu, Y.-L. Fu, and J. H. Schild 17{beta}-Estradiol restores excitability of a sexually dimorphic subset of myelinated vagal afferents in ovariectomized rats Am J Physiol Cell Physiol, January 1, 2009; 297(3): C654 - C664. [Abstract] [Full Text] [PDF]

				X. Fan, Y. Han, K. Sun, Y. Wang, Y. Xin, Y. Bai, W. Li, T. Yang, X. Song, H. Wang, et al. Sex Differences in Blood Pressure Response to Antihypertensive Therapy in Chinese Patients with Hypertension Ann. Pharmacother., December 1, 2008; 42(12): 1772 - 1781. [Abstract] [Full Text] [PDF]

				Y. Gui, X.-L. Zheng, J. Zheng, and M. P. Walsh Inhibition of rat aortic smooth muscle contraction by 2-methoxyestradiol Am J Physiol Heart Circ Physiol, November 1, 2008; 295(5): H1935 - H1942. [Abstract] [Full Text] [PDF]

				Z. F. Ba and I. H. Chaudry Role of estrogen receptor subtypes in estrogen-induced organ-specific vasorelaxation after trauma-hemorrhage Am J Physiol Heart Circ Physiol, November 1, 2008; 295(5): H2061 - H2067. [Abstract] [Full Text] [PDF]

				C. Baylis Sexual Dimorphism of the Aging Kidney: Role of Nitric Oxide Deficiency Physiology, June 1, 2008; 23(3): 142 - 150. [Abstract] [Full Text] [PDF]

				D. Z. I. Cherney, J. W. Scholey, R. Nasrallah, M. G. Dekker, C. Slorach, T. J. Bradley, R. L. Hebert, E. B. Sochett, and J. A. Miller Renal hemodynamic effect of cyclooxygenase 2 inhibition in young men and women with uncomplicated type 1 diabetes mellitus Am J Physiol Renal Physiol, June 1, 2008; 294(6): F1336 - F1341. [Abstract] [Full Text] [PDF]

				P. D. Patel and R. R. Arora Review: Endothelial dysfunction: A potential tool in gender related cardiovascular disease Therapeutic Advances in Cardiovascular Disease, April 1, 2008; 2(2): 89 - 100. [Abstract] [PDF]

				M. Coylewright, J. F. Reckelhoff, and P. Ouyang Menopause and Hypertension: An Age-Old Debate Hypertension, April 1, 2008; 51(4): 952 - 959. [Full Text] [PDF]

				M. A. Choudhry and I. H. Chaudry 17{beta}-Estradiol: a novel hormone for improving immune and cardiovascular responses following trauma-hemorrhage J. Leukoc. Biol., March 1, 2008; 83(3): 518 - 522. [Abstract] [Full Text] [PDF]

				H. Zhang and L. Zhang Role of Protein Kinase C Isozymes in the Regulation of alpha1-Adrenergic Receptor-Mediated Contractions in Ovine Uterine Arteries Biol Reprod, January 1, 2008; 78(1): 35 - 42. [Abstract] [Full Text] [PDF]

				O. Nevo, J. F. Soustiel, and I. Thaler Cerebral blood flow is increased during controlled ovarian stimulation Am J Physiol Heart Circ Physiol, December 1, 2007; 293(6): H3265 - H3269. [Abstract] [Full Text] [PDF]

				Y. Yuan and J. Xu Loss-of-Function Deletion of the Steroid Receptor Coactivator-1 Gene in Mice Reduces Estrogen Effect on the Vascular Injury Response Arterioscler Thromb Vasc Biol, July 1, 2007; 27(7): 1521 - 1527. [Abstract] [Full Text] [PDF]

				R. D. Anderson and C. J. Pepine Gender Differences in the Treatment for Acute Myocardial Infarction: Bias or Biology? Circulation, February 20, 2007; 115(7): 823 - 826. [Full Text] [PDF]

				A. E. Silver, S. D. Beske, D. D. Christou, A. J. Donato, K. L. Moreau, I. Eskurza, P. E. Gates, and D. R. Seals Overweight and Obese Humans Demonstrate Increased Vascular Endothelial NAD(P)H Oxidase-p47phox Expression and Evidence of Endothelial Oxidative Stress Circulation, February 6, 2007; 115(5): 627 - 637. [Abstract] [Full Text] [PDF]

				R. J. Paul, P. S. Bowman, J. Johnson, and A. F. Martin Effects of sex and estrogen on myosin COOH-terminal isoforms and contractility in rat aorta Am J Physiol Regulatory Integrative Comp Physiol, February 1, 2007; 292(2): R751 - R757. [Abstract] [Full Text] [PDF]

				R. E. Petre, M. P. Quaile, E. I. Rossman, S. J. Ratcliffe, B. A. Bailey, S. R. Houser, and K. B. Margulies Sex-based differences in myocardial contractile reserve Am J Physiol Regulatory Integrative Comp Physiol, February 1, 2007; 292(2): R810 - R818. [Abstract] [Full Text] [PDF]

				Z. F. Ba, A. Lu, T. Shimizu, L. Szalay, M. G. Schwacha, L. W. Rue III, K. I. Bland, and I. H. Chaudry 17beta-Estradiol modulates vasoconstriction induced by endothelin-1 following trauma-hemorrhage Am J Physiol Heart Circ Physiol, January 1, 2007; 292(1): H245 - H250. [Abstract] [Full Text] [PDF]

				L. Luksha, L. Poston, J.-A. Gustafsson, K. Hultenby, and K. Kublickiene The oestrogen receptor {beta} contributes to sex related differences in endothelial function of murine small arteries via EDHF J. Physiol., December 15, 2006; 577(3): 945 - 955. [Abstract] [Full Text] [PDF]

				D. N. Krause, S. P. Duckles, and D. A. Pelligrino Influence of sex steroid hormones on cerebrovascular function J Appl Physiol, October 1, 2006; 101(4): 1252 - 1261. [Abstract] [Full Text] [PDF]

				U. B. Berg Differences in decline in GFR with age between males and females. Reference data on clearances of inulin and PAH in potential kidney donors Nephrol. Dial. Transplant., September 1, 2006; 21(9): 2577 - 2582. [Abstract] [Full Text] [PDF]

				C. J. Pepine, W. W. Nichols, and D. F. Pauly Estrogen and Different Aspects of Vascular Disease in Women and Men Circ. Res., September 1, 2006; 99(5): 459 - 461. [Full Text] [PDF]

				J. Arnlov, M. J. Pencina, S. Amin, B.-H. Nam, E. J. Benjamin, J. M. Murabito, T. J. Wang, P. E. Knapp, R. B. D'Agostino Sr., S. Bhasin, et al. Endogenous sex hormones and cardiovascular disease incidence in men. Ann Intern Med, August 1, 2006; 145(3): 176 - 184. [Abstract] [Full Text] [PDF]

				T.-Y. Chun and J. H. Pratt Nongenomic Renal Effects of Aldosterone: Dependency on NO and Genomic Actions Hypertension, April 1, 2006; 47(4): 636 - 637. [Full Text] [PDF]

				L. C. Anderson, D. J. Martin, D. L. Phillips, K. J. Killpack, S. E. Bone, and R. Rahimian The influence of gender on parasympathetic vasodilatation in the submandibular gland of the rat Exp Physiol, March 1, 2006; 91(2): 435 - 444. [Abstract] [Full Text] [PDF]

				K. Hayashi, M. Miyachi, N. Seno, K. Takahashi, K. Yamazaki, J. Sugawara, T. Yokoi, S. Onodera, and N. Mesaki Variations in carotid arterial compliance during the menstrual cycle in young women Exp Physiol, March 1, 2006; 91(2): 465 - 472. [Abstract] [Full Text] [PDF]

				C. J. Pepine, R. A. Kerensky, C. R. Lambert, K. M. Smith, G. O. von Mering, G. Sopko, and C. N. Bairey Merz Some Thoughts on the Vasculopathy of Women With Ischemic Heart Disease J. Am. Coll. Cardiol., February 7, 2006; 47(3_Suppl_S): S30 - S35. [Abstract] [Full Text] [PDF]

				M. Senti, J. M. Fernandez-Fernandez, M. Tomas, E. Vazquez, R. Elosua, J. Marrugat, and M. A. Valverde Protective Effect of the KCNMB1 E65K Genetic Polymorphism Against Diastolic Hypertension in Aging Women and Its Relevance to Cardiovascular Risk Circ. Res., December 9, 2005; 97(12): 1360 - 1365. [Abstract] [Full Text] [PDF]

				A. Razmara, D. N. Krause, and S. P. Duckles Testosterone augments endotoxin-mediated cerebrovascular inflammation in male rats Am J Physiol Heart Circ Physiol, November 1, 2005; 289(5): H1843 - H1850. [Abstract] [Full Text] [PDF]

				L. Luksha, L. Poston, J.-A. Gustafsson, L. Aghajanova, and K. Kublickiene Gender-Specific Alteration of Adrenergic Responses in Small Femoral Arteries From Estrogen Receptor-{beta} Knockout Mice Hypertension, November 1, 2005; 46(5): 1163 - 1168. [Abstract] [Full Text] [PDF]

				A. K. Natoli, T. L. Medley, A. A. Ahimastos, B. G. Drew, D. J. Thearle, R. J. Dilley, and B. A. Kingwell Sex Steroids Modulate Human Aortic Smooth Muscle Cell Matrix Protein Deposition and Matrix Metalloproteinase Expression Hypertension, November 1, 2005; 46(5): 1129 - 1134. [Abstract] [Full Text] [PDF]

				B. A. Parker and D. N. Proctor Flow-mediated dilation J Appl Physiol, October 1, 2005; 99(4): 1620 - 1620. [Abstract] [Full Text] [PDF]

				W. Chai, I. M. Garrelds, R. de Vries, W. W. Batenburg, J. P. van Kats, and A.H. Jan Danser Nongenomic Effects of Aldosterone in the Human Heart: Interaction With Angiotensin II Hypertension, October 1, 2005; 46(4): 701 - 706. [Abstract] [Full Text] [PDF]

				D. G. Hemmings, S. J. Williams, and S. T. Davidge Increased myogenic tone in 7-month-old adult male but not female offspring from rat dams exposed to hypoxia during pregnancy Am J Physiol Heart Circ Physiol, August 1, 2005; 289(2): H674 - H682. [Abstract] [Full Text] [PDF]

				R. A. Khalil Sex Hormones as Potential Modulators of Vascular Function in Hypertension Hypertension, August 1, 2005; 46(2): 249 - 254. [Abstract] [Full Text] [PDF]

				A. Bouman, M. J. Heineman, and M. M. Faas Sex hormones and the immune response in humans Hum. Reprod. Update, July 1, 2005; 11(4): 411 - 423. [Abstract] [Full Text] [PDF]

				M. Coma, F. X. Guix, I. Uribesalgo, G. Espuna, M. Sole, D. Andreu, and F. J. Munoz Lack of oestrogen protection in amyloid-mediated endothelial damage due to protein nitrotyrosination Brain, July 1, 2005; 128(7): 1613 - 1621. [Abstract] [Full Text] [PDF]

				O. J. Kemi, P. M. Haram, J. P. Loennechen, J.-B. Osnes, T. Skomedal, U. Wisloff, and O. Ellingsen Moderate vs. high exercise intensity: Differential effects on aerobic fitness, cardiomyocyte contractility, and endothelial function Cardiovasc Res, July 1, 2005; 67(1): 161 - 172. [Abstract] [Full Text] [PDF]

				Z. F. Ba, T. Shimizu, L. Szalay, K. I. Bland, and I. H. Chaudry Gender differences in small intestinal perfusion following trauma hemorrhage: the role of endothelin-1 Am J Physiol Gastrointest Liver Physiol, May 1, 2005; 288(5): G860 - G865. [Abstract] [Full Text] [PDF]

				R. P. Brandes, I. Fleming, and R. Busse Endothelial aging Cardiovasc Res, May 1, 2005; 66(2): 286 - 294. [Abstract] [Full Text] [PDF]

				V. H. Huxley, J. Wang, and S. P. Whitt Sexual dimorphism in the permeability response of coronary microvessels to adenosine Am J Physiol Heart Circ Physiol, April 1, 2005; 288(4): H2006 - H2013. [Abstract] [Full Text] [PDF]

				K. Narkiewicz, B. G. Phillips, M. Kato, D. Hering, L. Bieniaszewski, and V. K. Somers Gender-Selective Interaction Between Aging, Blood Pressure, and Sympathetic Nerve Activity Hypertension, April 1, 2005; 45(4): 522 - 525. [Abstract] [Full Text] [PDF]

				L. L. Gibson, L. Hahner, S. Osborne-Lawrence, Z. German, K. K. Wu, K. L. Chambliss, and P. W. Shaul Molecular Basis of Estrogen-Induced Cyclooxygenase Type 1 Upregulation in Endothelial Cells Circ. Res., March 18, 2005; 96(5): 518 - 525. [Abstract] [Full Text] [PDF]

				T. Shimizu, L. Szalay, M. A. Choudhry, M. G. Schwacha, L. W. Rue III, K. I. Bland, and I. H. Chaudry Mechanism of salutary effects of androstenediol on hepatic function after trauma-hemorrhage: role of endothelial and inducible nitric oxide synthase Am J Physiol Gastrointest Liver Physiol, February 1, 2005; 288(2): G244 - G250. [Abstract] [Full Text] [PDF]

				J. F. Reckelhoff Sex Steroids, Cardiovascular Disease, and Hypertension: Unanswered Questions and Some Speculations Hypertension, February 1, 2005; 45(2): 170 - 174. [Full Text] [PDF]

This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Web of Science (134) Citing Articles via Google Scholar Google Scholar Articles by Orshal, J. M. Articles by Khalil, R. A. Search for Related Content PubMed PubMed Citation Articles by Orshal, J. M. Articles by Khalil, R. A.